A BETTER THERAPY PLATFORM.
A BETTER PROGRAMMING EXPERIENCE. FOR EVERYONE.¹

St. Jude Medical Infinity™ DBS system

Learn more | Visit Booth C.02


Abbott
One St. Jude Medical Dr., St. Paul, MN 55177 USA, Tel: 1 651 756 2000
SJM.com
St. Jude Medical is now Abbott.

Rx Only
Brief Summary: Prior to using these devices, please review the clinician’s manual for a complete listing of indications, contraindications, warnings, precautions, potential adverse events, and directions for use. The system is intended to be used with leads and associated extensions that are compatible with the system.

™ Indicates a trademark of the Abbott group of companies.
† Indicates a third party trademark, which is property of its respective owner.
© 2018 Abbott. All Rights Reserved.

28299-SJMFN-0318-0001a | Item approved for international use only.
## TABLE OF CONTENTS

**Welcome Words** ............................................................... 05

### Scientific Program

- **Floor Plan** ............................................................ 08
- **Session Descriptions and Types** .................................. 09

- **Sunday, 19 August 2018, Program Overview** .................. 10
- **Sunday, 19 August 2018, Scientific Program** .................. 11
- **Monday, 20 August 2018, Program Overview** ................ 12
- **Monday, 20 August 2018, Scientific Program** ................ 13
- **Tuesday, 21 August 2018, Program Overview** ................. 20
- **Tuesday, 21 August 2018, Scientific Program** ............... 21
- **Wednesday, 22 August 2018, Program Overview** ............ 28
- **Wednesday, 22 August 2018, Scientific Program** .......... 28

- **Poster Exhibition** .................................................. 31
- **Information for Abstract Authors** ............................... 50
- **Information for Speakers / Speakers Centre** ................ 51
- **Index of Authors and Speakers** ................................ 52

### General Congress Information

- **Registration** .......................................................... 60
- **Travel Grants** ...................................................... 61
- **How to get there** .................................................. 62
- **Good to know** ...................................................... 63

### IAPRD Association

- **About the International Association of Parkinsonism and Related Disorders** ............. 68
- **IAPRD Committees** ............................................... 70

### Industry

- **List of Exhibitors and Map** ..................................... 74
- **List of Sponsors and Supporters** ............................... 76
- **Corporate Sessions** .............................................. 77

- **Imprint and Data Protection** .................................... 78
On behalf of the Board of the International Association of Parkinsonism and Related Disorders, it is our pleasure to welcome you for an exciting and comprehensive educational program at the XXIII World Congress on Parkinson’s Disease and Related Disorders in Lyon, France!

Lyon, the second largest city in France, is situated in the Auvergne-Rhône-Alpes region at the confluence of the Rhône and Saône Rivers. Lyon was the ancient capital of Roman Gaul and has a rich and long-standing history. Today, Lyon is a dynamic city attracting an increasing number of companies and talent, notably in biotechnologies. These features attract clinicians and scientists from around the world to gain insights, learn from one another, and advance the field of movement disorders for the benefit of patients worldwide.

The Congress will begin each morning and afternoon with Plenary Sessions providing overviews of the phenomenology, pathophysiology, and current diagnostic and therapeutic strategies of various movement disorders. These sessions will be followed by Parallel Tracks, permitting participants to select specific diagnostic or therapeutic areas for more concentrated study. A highlight of the Congress will be the Grand Parade of Movement Disorders — an evening video session during which faculty and attendees will showcase the most interesting presentations of movement disorders from around the world. Experts will present Skills Workshops — practical sessions on deep brain stimulation surgeries, pump technologies, and botulinum toxin injections — as well as demonstrations on how to examine patients with movement disorders!

The final day will begin with Plenary Sessions on the emerging diagnostic tools and therapies in Parkinson disease and other movement disorders. We will finish with powerful debates on controversial issues facing our specialty today. The Congress will also offer Meet the Professor Sessions to allow young clinicians and scientists to interact with and learn from accomplished senior faculty members. Oral Poster Sessions will allow delegates a chance to share their research discoveries and observations, and Sponsored Sessions will update delegates on the latest areas of focus from our industry partners.

We look forward to an educational and interactive Congress in this beautiful city. Thank you very much for your participation and enjoy the spirit of summer!
1. Main Entrance
2. Registration / Cloak Room
3. Auditorium Lumière
4. Speakers Centre
5. Forum 1
6. Forum 2
7. Forum 3 / Exhibition
8. Foyer Forum
PLENARY SESSIONS
These sessions will include lectures on phenomenology, and overviews of the pathophysiology, diagnostic and therapeutic approaches to various movement disorders. Each lecture within a plenary theme will be 30 minutes (25 minutes of didactic followed by 5 minutes of Q and A), delivered by world-renowned faculty members.

PARALLEL TRACKS
The sessions within a track are arranged to provide a deep dive into a diagnostic or therapeutic area. Each session will be 30 minutes of interactive lecture (25 minutes of didactic followed by 5 minutes of Q and A).

GRAND PARADE OF MOVEMENT DISORDERS
An evening video session where both faculty and attendees present pre-selected cases from around the globe to showcase the amazing breadth of movement disorders. This event will be co-hosted by two of our most astute and experienced clinical experts.

SKILLS WORKSHOP
Each of these sessions will provide 1.5 hours of practical information and/or demonstrations on the proper utilization of botulinum toxin, deep brain stimulation surgery, pump therapy in Parkinson disease, ultrasound application in movement disorders, and the optimal examination of patients with hypo- and hyperkinetic disorders.

COFFEE WITH THE PROFESSOR
These are brief mentoring sessions sprinkled throughout the duration of the Congress where young and aspiring clinicians and scientists can engage with a renowned faculty member, in a relaxed setting, over a cup of coffee.

Corporate Sessions (over Lunch)
These sessions, sponsored by our industry partners, will all be held during lunchtime.

ORAL POSTER SESSIONS
Poster authors are expected to present their poster and answer questions by the moderator as well as by the audience of the Oral Poster Session Tour. The author or presenter must be registered for the congress.

PARKINSONISM AND RELATED DISORDERS JOURNAL:
SPECIAL SESSION AND AWARDS
A tour de force compilation of the most relevant 2017-2018 articles in Parkinsonism and Related Disorders. Awards will also be given during this session to the Best Clinical Poster and Best Basic/Translation Science Poster prior.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Auditorium Lumière</th>
<th>Forum 1</th>
<th>Forum 2</th>
<th>Foyer Forum</th>
<th>Exhibition Forum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00 – 12:30</td>
<td>IAPRD Annual General Meeting (for full IAPRD members only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30 – 13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 – 15:00</td>
<td>The Structure and Function of the Basal Ganglia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00 – 15:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30 – 17:00</td>
<td>Clinical Presentations of Basal Ganglia Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00 – 17:30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30 – 19:00</td>
<td>Opening Ceremony / Melvin Yahr Lectures</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SCIENTIFIC PROGRAM / SUNDAY, 19 AUGUST 2018

13:30 – 15:00

Plenary Session Auditorium Lumière

The Structure and Function of the Basal Ganglia
Chair: Peter Riederer, Wuerzburg, Germany
Chair: Thomas Bruecke, Vienna, Austria

Untangling the Neurophysiology of the Basal Ganglia
Speaker: Hagai Bergman, Jerusalem, Israel

Deconstructing the Neurochemistry of the Basal Ganglia
Speaker: Angela Cenci-Nilsson, Lund, Sweden

Basal Ganglia Circuits: A Review with Lessons from Neuromodulation
Speaker: Michael Okun, Gainesville, United States

15:30 – 17:00

Clinical Presentations of Basal Ganglia Disorders
Chair: Erik Ch. Wolters, Amsterdam, The Netherlands
Chair: Marie Vidailhet, Paris, France

Motor Manifestations of Basal Ganglia Disorders
Speaker: Hui-Fang Shang, Chengdu, Sichuan, China

Behavioral Manifestations of Basal Ganglia Disorders
Speaker: Ergun Uc, Iowa City, United States

Cognitive Dysfunction in Basal Ganglia Disorders
Speaker: Jennifer Goldman, Chicago, United States

17:30 – 19:00

Opening Ceremony / Melvin Yahr Lectures
Chair: Hubert Fernandez, Cleveland, United States
Chair: Elena Moro, Grenoble, France

Welcome message by Daniel Truong, President IAPRD, Elena Moro, Congress
Chair and Emmanuel Broussolle, on behalf of the Local Organizing Committee

Lifetime Achievement Award
The Brain and Passage of Time
Speaker: Yves Agid, Paris, France

Melvin Yahr Lecture I
My Gut Reaction: The Story of Parkinson Disease from Mouth to the Colon
Speaker: Ronald Pfeiffer, Portland, United States

Melvin Yahr Lecture II
Searching for the Holy Grail: Lessons Learned from My Journey as a Clinician Scientist
Speaker: Michael Schwarzschild, Boston, United States

At the end of the Opening Ceremony all participants are invited to join the Networking Reception in the exhibition area.
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Auditorium Lumière</th>
<th>Forum 1</th>
<th>Forum 2</th>
<th>Foyer Forum</th>
<th>Exhibition Forum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td></td>
<td>Parkinsonism –</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Capturing the Giant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>Coffee with</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>the Professor</td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td>Imaging and Pathology in Parkinson Disorders</td>
<td>Other Diagnostic Tools in Parkinson Disorders</td>
<td>Examining the Parkinsonian Patient</td>
<td>Oral Poster Session I – Behavior and Cognition, Deep Brain Stimulation</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td>Corporate Session 1</td>
<td></td>
<td></td>
<td>Corporate Session 2</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td>PD and Parkinson-Plus Therapy – Current Treatments for PD and Parkinson-Plus Syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>Coffee with</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>the Professor 2</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td></td>
<td>Challenging Features in Parkinsonian Disorders</td>
<td>Alternative and Palliative Therapies in Parkinson Disease</td>
<td>Gastrointestinal Issues in Parkinson Disease supported by Merz Pharmaceuticals GmbH with an unrestricted grant</td>
<td>Oral Poster Session II – Ataxias, Tics, and/or Myoclonus, Dystonia, Gait and Other MD, Tremors</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>Coffee with</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>the Professor 3</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td></td>
<td>Parkinson Disease Care in Unique Settings</td>
<td>Practical Issues on Deep Brain Stimulation Therapy for PD</td>
<td>Pumps and Infusions in Parkinson Disease</td>
<td>Oral Poster Session III – Parkinson Disease</td>
<td></td>
</tr>
</tbody>
</table>

- **Plenary Session**
- **Skills Workshop**
- **Parallel Track**
- **Oral Poster Session**
- **Grand Parade Session**
- **Coffee with the Professor**
- **Corporate Sessions (over Lunch)**

**Program Overview / Monday, 20 August 2018**
SCIENTIFIC PROGRAM / MONDAY, 20 AUGUST 2018

Plenary Session  Auditorium Lumière

08:00 – 10:00  Parkinsonism – Capturing the Giant
Chair: Elena Moro, Grenoble, France
Chair: Daniel Truong, Fountain Valley, United States

08:00 – 08:30  The Colorful Clinical Spectrum of Parkinsonism
Speaker: Roongroj Bhidayasiri, Bangkok, Thailand

08:30 – 09:00  Revisiting the Definition of Parkinson Disease
Speaker: Daniela Berg, Tübingen, Germany

09:00 – 09:30  Victories and Losses in the Search for Elusive Parkinson Biomarkers
Speaker: Lorraine Kalia, Toronto, Canada

09:30 – 10:00  Environment and Genes: How They Create the Perfect Storm
Speaker: Caroline Tanner, San Francisco, United States

Coffee with the Professor  Foyer Forum

10:00 – 10:30  Coffee with the Professor 1
Kailash Bhatia, London, United Kingdom

Parallel Tracks  Auditorium Lumière

10:30 – 12:00  Imaging and Pathology in Parkinsonian Disorders
Chair: Ioannis Isaias, Wuerzburg, Germany

10:30 – 11:00  Focus on Morphological Imaging in Parkinsonian Disorders
Speaker: Stephane Lehericy, Paris, France

11:00 – 11:30  Focus on Functional Imaging in Parkinsonian Disorders
Speaker: Stephane Thobois, Lyon, France

11:30 – 12:00  Current Pathological Understanding of Parkinsonian Disorders
Speaker: Peter Riederer, Wuerzburg, Germany

Parallel Tracks  Forum 1

10:30 – 12:00  Other Diagnostic Tools in Parkinsonian Disorders
Chair: Raymond Rosales, Quezon City, Philippines

10:30 – 11:00  How Sleep Studies are Shedding Light on our Understanding of Parkinsonian Disorders
Speaker: Ronald Postuma, Montreal, Canada

11:00 – 11:30  Can the Gut be the Missing Piece in Uncovering PD Pathogenesis?
Speaker: Pascal Derkinderen, Nantes, France

11:30 – 12:00  Acknowledging the Giant Elephant:
The Utility of Cognitive and Behavioral Assessments in PD
Speaker: Jaime Kulisevsky, Barcelona, Spain
**Skills Workshop**

**Forum 2**

10:30 – 12:00  **Examining the Parkinsonian Patient**
Chair: Shinsuke Fujioka, Fukuoka, Japan

10:30 – 11:00  **How To Examine a Parkinsonian Patient Like an Expert**
Speaker: Leonard Verhagen, Chicago, United States

11:00 – 11:30  **Recognizing Red Flags that Suggest Parkinson-Plus Syndromes**
Speaker: Roongroj Bhidayasiri, Bangkok, Thailand

11:30 – 12:00  **Learning from Experience: Pitfalls and Misconceptions in Parkinsonian Presentations**
Speaker: Alberto Albanese, Milan, Italy

**Oral Poster Presentation**

**Foyer Forum**

10:30 – 12:00  **Oral Poster Session I – Behavior and Cognition, Deep Brain Stimulation**
Moderator: Daniel Weintraub, Philadelphia, United States
Moderator: Raja Mehanna, Houston, United States

**OP-01**

**OP-01-01**  **Freezing of gait in Parkinson's disease: Is it just a motor problem or more?**
Speaker: Moulika Mandal, Mumbai, India

**OP-01-03**  **Cognition in subjects with REM sleep behavior disorder and cumulative signs of prodromal Parkinson's disease**
Speaker: Géraldine Hipp, Belvaux, Luxembourg

**OP-01-04**  **Visuospatial working memory and executive function deficits in single-versus multiple-domain amnestic mild cognitive impairment: A combined ERP and sLORETA study**
Speaker: Lihua Gu, Nanjing, China

**OP-01-05**  **Cognitive and histopathological phenotypes in new rat models of cortical synucleinopathy**
Speaker: M. Angela Cenci, Lund, Sweden

**OP-01-06**  **Association between post-operative delirium and Parkinson disease following common US surgical procedures**
Speaker: Bhavpreet Dham, Rochester, United States

**OP-01-07**  **Cortical 123I-FP-CIT binding deficits are associated with mild cognitive impairment in Parkinson's disease**
Speaker: Andrea Pilotto, Brescia, Italy

**OP-01-08**  **Subthalamic deep brain stimulation for advanced Parkinson’s disease beyond the 5-year follow-up**
Speaker: Anna Gamaleya, Moscow, Russian Federation

**OP-01-09**  **Deep brain stimulation of the nucleus basalis of Meynert as a treatment for Parkinson's Disease Dementia: A systematic review of animal studies**
Speaker: Muhammad Nazmuddin, Groningen, Netherlands
OP-01-10  Long-term effect of subthalamic deep brain stimulation in young- and late-onset Parkinson’s disease: 10-year follow-up study  
Speaker: Mi Sun Kim, Seoul, Republic of Korea

OP-01-11  Bilateral GPi DBS improves medically intractable postural and kinetic tremor in patients with Parkinson’s disease  
Speaker: Chong Sik Lee, Seoul, Republic of Korea

OP-01-12  Non-motor symptoms in dystonia patients and influence of deep brain stimulation and botulinum toxin on them  
Speaker: Vladimira Vuletic, Rijeka, Croatia

OP-01-13  The subthalamic nucleus activity at gait initiation in Parkinson’s disease  
Speaker: Ioannis Isaias, Wuerzburg, Germany

OP-01-14  Long-term clinical outcome of deep brain stimulation for PKAN syndrome  
Speaker: Victoria Gonzalez, Montpellier, France

OP-01-15  Finding ways to improve axial symptoms in patients with chronic STN DBS for Parkinson’s disease  
Speaker: Jessica Karl, Chicago, United States

OP-01-16  Battery longevity of neurostimulators in Parkinson disease: A historic cohort study  
Speaker: Anna Luce Sette, Grenoble, France

OP-01-17  Suicide after STN-DBS in Parkinson disease: Who, when and how to prevent?  
Speaker: Giulia Giannini, Bologna, Italy

Corporate Session  Forum 1
12:15 – 13:45  Corporate Session 1: Please see page 77

Corporate Session  Forum 2
12:15 – 13:15  Corporate Session 2: Please see page 77

Plenary Session  Auditorium Lumière
Chair: Tanya Simuni, Chicago, United States  
Chair: Franck Durif, Clermont Ferrand, France

13:45 – 14:15  Current Approach to PD Motor Treatment: An Emerging Consensus?  
Speaker: Marcelo Merello, Buenos Aires, Argentina

14:15 – 14:45  Addressing the Behavioral and Cognitive Complications in PD  
Speaker: Irena Rektorova, Brno, Czech Republic

14:45 – 15:15  Progress in the Treatment of Parkinson-Plus Syndromes  
Speaker: Irene Litvan, San Diego, United States
15:15 – 15:45  
**Coffee with the Professor 2**  
*Caroline Tanner, San Francisco, United States*

15:45 – 17:15  
**Parallel Tracks**  
*Auditorium Lumière*

15:45 – 17:15  
**Challenging Features in Parkinsonian Disorders**  
*Chair: Pramod Pal, Bengaluru, Karnataka, India*

15:45 – 16:15  
**Preventing Falls and Fractures: The Approach to Freezing and Gait Instability**  
*Speaker: Ioannis Isaias, Wuerzburg, Germany*

16:15 – 16:45  
**A Deep Dive into the Sea of Dysautonomic Complication in PD**  
*Speaker: Paola Sandroni, New York, United States*

16:45 – 17:15  
**Sensible Strategies for Sleep Dysfunction in the PD Patient**  
*Speaker: Christian Baumann, Zurich, Switzerland*

15:45 – 17:15  
**Parallel Tracks**  
*Forum 1*

15:45 – 17:15  
**Alternative and Palliative Therapies in Parkinson Disease**  
*Chair: Hrishikesh Kumar, West Bengal, India*

15:45 – 16:15  
**The Evidence of Exercise in Enhancing the Management of PD**  
*Speaker: Bettina Debu, Grenoble, France*

16:15 – 16:45  
**The Ever Expanding Role of Botulinum Toxins in Parkinsonian Disorders**  
*Speaker: Mark Lew, Los Angeles, United States*

16:45 – 17:15  
**Completing the Chapter of Care: End of Life Issues in PD**  
*Speaker: Miguel Coelho, Lisbon, Portugal*

15:45 – 17:15  
**Parallel Tracks**  
*Forum 2*

15:45 – 17:15  
**Gastrointestinal Issues in Parkinson Disease**  
*Supported by Merz Pharmaceuticals GmbH with an unrestricted grant*  
*Chair: Ronald Pfeiffer, Portland, United States*

15:45 – 16:15  
**How Relevant is Nutrition in PD Care and Management?**  
*Speaker: Emanuele Cereda, Pavia, Italy*

16:15 – 16:45  
**Upper Gastrointestinal Challenges in Parkinson Disease**  
*Speaker: Heinz Reichmann, Dresden, Germany*

16:45 – 17:15  
**Lower Gastrointestinal Challenges in Parkinson Disease**  
*Speaker: Ronald Pfeiffer, Portland, United States*

15:45 – 17:15  
**Oral Poster Presentation**  
*Foyer Forum*

15:45 – 17:15  
**Oral Poster Session II – Ataxias, Tics, and/or Myoclonus, Dystonia, Gait and Other Movement Disorders, Tremors**  
*(4 minutes oral presentations followed by 1 minute Q&A)*  
*Moderator: Maria Stamou, Athens, Greece*  
*Moderator: Diego Torres-Russotto, Omaha, United States*
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Speaker</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>OP-02-02</td>
<td>Frequencies, genetic, clinical and radiologic characterization of spinocerebellar ataxia in Korea</td>
<td>Minkyeong Kim, Seoul, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>OP-02-04</td>
<td>Subcortical brain areas correlate genetic characteristics in spinocerebellar ataxia type 2 patients</td>
<td>Dibashree Tamuli, New Delhi, India</td>
<td></td>
</tr>
<tr>
<td>OP-02-05</td>
<td>Clinical and genetic aspects of Huntington’s disease in 11 Malian families: The largest cohort genetically confirmed in Sub-Saharan Africa</td>
<td>Abdoulaye Bocoum, Bamako, Mali</td>
<td></td>
</tr>
<tr>
<td>OP-02-06</td>
<td>Immunogenicity of daxibotulinumtoxinA for injection in adults with cervical dystonia from a phase 2 dose-escalation multicenter study</td>
<td>Dirk Dressler, Hannover, Germany</td>
<td></td>
</tr>
<tr>
<td>OP-02-07</td>
<td>Intero- and exteroceptive mirroring and overflow movements are useful in assessing writer’s cramp</td>
<td>Shi-Ni Tan, Singapore, Singapore</td>
<td></td>
</tr>
<tr>
<td>OP-02-08</td>
<td>Hyperkinetic movement disorders induced by mirtazapine: Unusual case report and clinical analysis of reported cases</td>
<td>Won Tae Yoon, Seoul, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>OP-02-09</td>
<td>Deep brain stimulation parameters for dystonia: A systematic review</td>
<td>Bakhtigul Kholmuratova, Tashkent, Uzbekistan</td>
<td></td>
</tr>
<tr>
<td>OP-02-10</td>
<td>Approach to health care shaped by Generational Expectations (the AGE study): Patients’ preferences for healthcare providers</td>
<td>Diana Hengartner, Cleveland, United States</td>
<td></td>
</tr>
<tr>
<td>OP-02-11</td>
<td>Effects of long-term valbenazine on tardive dyskinesia and patient-reported outcomes: Results from the KINECT 4 study</td>
<td>Scott Siegert, San Diego, United States</td>
<td></td>
</tr>
<tr>
<td>OP-02-13</td>
<td>The neural mechanism of freezing of gait in patients with Parkinson’s disease</td>
<td>Nicolò G. Pozzi, Wuerzburg, Germany</td>
<td></td>
</tr>
</tbody>
</table>

**Coffee with the Professor**

Coffee with the Professor Foyer Forum

17:15 – 17:45

**Coffee with the Professor 3**

Vincenzo Bonifati, Rotterdam, The Netherlands

**Skills Workshop**

Skills Workshop Forum 1

17:45 – 19:15

**Practical Issues in Deep Brain Stimulation Therapy for PD**

Chair: Elena Moro, Grenoble, France

17:45 – 18:15

**Patient Selection: Combining Evidence with Experience**

Speaker: Jens Volkmann, Wuerzburg, Germany

18:15 – 18:45

**Pearls and Pitfalls in DBS Programming**

Speaker: Joohi Jimenez-Shahed, Houston, United States

18:45 – 19:15

**When Things Don’t Go As Planned: Troubleshooting in DBS**

Speaker: Raja Mehanna, Houston, United States
Skills Workshop Forum 2

17:45 – 19:15  **Pumps and Infusions in Parkinson Disease**
    Chair: **Thomas Mueller, Berlin, Germany**

17:45 – 18:15  **Apomorphine Infusion: Setting up and Troubleshooting**
    Speaker: **Marcelo Merello, Buenos Aires, Argentina**

18:15 – 18:45  **Levodopa Intestinal Gel: Setting up and Troubleshooting**
    Speaker: **David Grabli, Paris, France**

18:45 – 19:15  **Which Pump to Use? Optimal Patient Selection for Each Advanced Therapy**
    Speaker: **Emmanuel Flamand-Roze, Paris, France**

Parallel Tracks Auditorium Lumière

17:45 – 19:15  **Parkinson Disease Care in Unique Settings**
    Chair: **Yaroslau Compta Hirnyi, Barcelona, Spain**

17:45 – 18:15  **When Time is of the Essence: Managing Care in Emergency Situations**
    Speaker: **Pramod Pal, Bengaluru, Karnataka, India**

18:15 – 18:45  **What To Do When Your Parkinson Patient Has To Undergo Surgery: From Pre- to Post-Operative State**
    Speaker: **Leonard Verhagen, Chicago, United States**

18:45 – 19:15  **Are We Really Ready for Telemedicine and Distance Health?**
    Speaker: **Mark Guttman, Toronto, Canada**

Oral Poster Presentation Foyer Forum

17:45 – 19:15  **Oral Poster Session III – Parkinson Disease**
    (4 minutes oral presentations followed by 1 minute Q&A)
    Moderator: **Rupam Borgohain, Hyderabad, India**
    Moderator: **Theresa Zesiewicz, Tampa, United States**

**OP-03-01**  **Nilotinib increases dopamine metabolism and reduces oligomeric:total alpha-synuclein ratio in Parkinson’s disease**
    Speaker: **Fernando Pagan, Washington DC, United States**

**OP-03-02**  **Clinical subtypes of excessive daytime sleepiness in Parkinson’s disease**
    Speaker: **Olga Iakovleva, Moscow, Russian Federation**

**OP-03-03**  **Neuroprotective effects of Ethnodyn Neuro® (SNC-1), a natural product used in ayurvedic traditional medicine, on in vitro models of Parkinson’s disease**
    Speaker: **Alexandre Henriques, Gardanne, France**

**OP-03-04**  **Propensity of Mucuna Pruriens to offset rotenone-induced biochemical, behavioral and oxidative dysfunctions in mice: Implications for Parkinson’s disease**
    Speaker: **Dharmendra Khatri, Mumbai, India**
OP-03-05  **Effect of Tai Chi exercise to reduce falls and improve balance performance in Parkinson's disease: A meta-analysis**  
Speaker: Hsin-Hsuan Liu, Taipei, Taiwan

OP-03-06  **Is Parkinson’s disease with history of agent orange exposure different from idiopathic Parkinson’s disease?**  
Speaker: YoungSoon Yang, Seoul, Republic of Korea

OP-03-07  **α-Synuclein induced dopaminergic neurons mitochondrial dysfunction via cytochrome c oxidase subunit 2**  
Speaker: Danyu Lin, Guangzhou, China

OP-03-08  **Dopaminergic treatment and speech in Parkinson’s disease: Acoustic analysis and correlation with motor features and dyskinesia**  
Speaker: Francesco Cavallieri, Modena, Italy

OP-03-09  **Video game-based dexterity training in patients with Parkinson’s disease: A pilot feasibility study**  
Speaker: Judith Jantine Willemijn van Beek, Lucerne, Switzerland

OP-03-10  **PROtein, LEucine And vitamin D Enhancing Rehabilitation (PRO-LEADER) in patients with Parkinson’s disease or parkinsonism: An RCT**  
Speaker: Emanuele Cereda, Pavia, Italy

OP-03-11  **Parkinson's disease: Social determinants of quality of life of patients in the central belt of Ghana**  
Speaker: Vida Obese, Kumasi, Ghana

OP-03-12  **Exploration of the regulation of miR-4639-5p expression and its role in the pathogenesis of Parkinson’s disease**  
Speaker: Lu He, Shanghai, China

OP-03-13  **Biochemical studies in the brain of transgenic drosophila as a model of Parkinson’s disease treated by ropinirole silver nanocomposite (RAgNC)**  
Speaker: Falaq Naz, Aligarh, India

OP-03-14  **Rifampicin inhibits rotenone-induced inflammation by improving lysosomal function and autophagic flux in microglia**  
Speaker: Yanran Liang, Guangzhou, China

OP-03-15  **Effects of transcranial magnetic stimulation on hypokinetic dysarthria in Parkinson’s disease**  
Speaker: Lubos Brabenec, Brno, Czech Republic

OP-03-16  **Bradykinesia assessment using evolutionary algorithms in Parkinson’s disease: Clinical validation**  
Speaker: Chao Gao, Shanghai, China

OP-03-18  **Genomic variants associated with cognitive impairment in Parkinson’s disease**  
Speaker: Sun Ju Chung, Seoul, Republic of Korea

OP-03-19  **Tear proteins as possible biomarkers for Parkinson’s disease**  
Speaker: Mark Lew, Los Angeles, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Auditorium Lumière</th>
<th>Forum 1</th>
<th>Forum 2</th>
<th>Foyer Forum</th>
<th>Exhibition Forum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td></td>
<td>Hyperkinetic Disorders I – The Three Other Giants: Chorea, Tics and Dystonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>Coffee with the Professor 4</td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td></td>
<td>Revisiting Tardive Dyskinesias</td>
<td>Botulinum Toxin Use in Hyperkinetic Disorders</td>
<td>Examining the Hyperkinetic Patient</td>
<td>Oral Poster Session IV – Imaging, Genetics and Biomarkers, Other Parkinsonian Disorders</td>
<td></td>
</tr>
<tr>
<td>12:00 – 12:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 – 13:45</td>
<td></td>
<td></td>
<td>Corporate Session 3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15 – 15:45</td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td>Coffee with the Professor 5</td>
<td></td>
</tr>
<tr>
<td>15:45 – 17:15</td>
<td></td>
<td>Other Hyperkinetic Disorders</td>
<td>Surgical Therapies for Hyperkinetic Disorders</td>
<td>Rare and Misdiagnosed Movement Disorders</td>
<td>Oral Poster Session V – Parkinson Disease</td>
<td></td>
</tr>
<tr>
<td>17:15 – 18:00</td>
<td></td>
<td>Spotlight Debate: Should we worry that pimavanserin might indeed increase mortality amongst Parkinson patients with psychosis? supported by Acadia® Pharmaceuticals with an unrestricted grant</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00 – 20:00</td>
<td></td>
<td>Grand Parade of Movement Disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Room Colors:**
- Blue: Plenary Session
- Purple: Grand Parade Session
- Green: Corporate Sessions (over Lunch)
- Yellow: Parallel Track
- Beige: Coffee with the Professor
- Brown: Oral Poster Session

**Time Periods:**
- 08:00 – 10:00: Plenary Session
- 10:00 – 10:30: Coffee Break
- 10:30 – 12:00: Parallel Track
- 12:00 – 12:15: Oral Poster Session
- 12:15 – 13:45: Skills Workshop
- 13:45 – 17:15: Corporate Sessions (over Lunch)
- 17:15 – 18:00: Grand Parade Session
- 18:00 – 20:00: Wine and Cheese Reception
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td><strong>Hyperkinetic Disorders I – The Three Other Giants: Chorea, Tics and Dystonia</strong>&lt;br&gt;Chair: Raymond Rosales, Quezon City, Philippines&lt;br&gt;Chair: Vincenzo Bonifati, Rotterdam, The Netherlands</td>
<td>Auditorium Lumière</td>
</tr>
<tr>
<td>08:00 – 08:30</td>
<td><strong>Meeting The Diverse Family of Hyperkinetic Disorders</strong>&lt;br&gt;Speaker: Kailash Bhatia, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>08:30 – 09:00</td>
<td><strong>Greatest Lessons Learned in Huntington’s Disease</strong>&lt;br&gt;Speaker: Tiago Mestre, Ottawa, Canada</td>
<td></td>
</tr>
<tr>
<td>09:00 – 09:30</td>
<td><strong>Tics, Tourette’s and Stereotypies: Birds of the Same Feather that Do Not Flock Together</strong>&lt;br&gt;Speaker: Davide Martino, Calgary, Canada</td>
<td></td>
</tr>
<tr>
<td>09:30 – 10:00</td>
<td><strong>The Colorful Spectrum of Dystonia and the Evolution of its Classification</strong>&lt;br&gt;Speaker: Marie Vidailhet, Paris, France</td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td><strong>Coffee with the Professor</strong>&lt;br&gt;Tanya Simuni, Chicago, United States</td>
<td>Foyer Forum</td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td><strong>Botulinum Toxin Use in Hyperkinetic Disorders</strong>&lt;br&gt;Chair: Dirk Dressler, Hannover, Germany</td>
<td>Auditorium Lumière</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td><strong>Do’s and Don’ts in Botulinum Toxin Injections for Cervical Dystonia</strong>&lt;br&gt;Speaker: Joohi Jimenez-Shahed, Houston, United States</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td><strong>Injection Principles When Targeting the Face and Mouth</strong>&lt;br&gt;Speaker: Dirk Dressler, Hannover, Germany</td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td><strong>Pearls and Pitfalls in Botulinum Toxin Injections for Limb Dystonia and Spasticity</strong>&lt;br&gt;Speaker: Raymond Rosales, Quezon City, Philippines</td>
<td></td>
</tr>
<tr>
<td>10:30 – 12:00</td>
<td><strong>Revisiting Tardive Dyskinesias</strong>&lt;br&gt;Chair: Emmanuel Broussolle, Lyon, France</td>
<td>Auditorium Lumière</td>
</tr>
<tr>
<td>10:30 – 11:00</td>
<td><strong>Setting the Record Straight: Nosology of Tardive Syndrome</strong>&lt;br&gt;Speaker: Daniel Truong, Fountain Valley, United States</td>
<td></td>
</tr>
<tr>
<td>11:00 – 11:30</td>
<td><strong>Who Gets It and Why? A Review of the Risk Factors and Hypothesized Mechanisms for Tardive Dyskinesias</strong>&lt;br&gt;Speaker: Karen Frei, Loma Linda, United States</td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:00</td>
<td><strong>Current Treatment Options for Tardive Dyskinesias</strong>&lt;br&gt;Speaker: Hubert Fernandez, Cleveland, United States</td>
<td></td>
</tr>
</tbody>
</table>
Skills Workshop Forum 2

10:30 – 12:00 Examining the Hyperkinetic Patient
Chair: Irena Rektorova, Brno, Czech Republic

10:30 – 11:00 How To Examine the Hyperkinetic Patient Like a Master Clinician
Speaker: Zoltan Mari, Cleveland, United States

11:00 – 11:30 Recognizing Clues from the Eyes: Ophthalmological Examination in Movement Disorders
Speaker: Vivek Lal, Chandigarh, India

11:30 – 12:00 Making a Confident Diagnosis of Functional Movement Disorders through Signs and Symptoms
Speaker: Alberto Espay, Cincinnati, United States

Oral Poster Presentation Foyer Forum

10:30 – 12:00 Oral Poster Session IV – Imaging, Genetics and Biomarkers, Other Parkinsonian Disorders
(4 minutes oral presentations followed by 1 minute Q&A)
Moderator: Jennifer Goldman, Chicago, United States
Moderator: Eng-King Tan, Singapore, Singapore

OP-04-01 Imaging biomarkers for freezing of gait in patients with Parkinson’s disease
Speaker: Ruwei Ou, Chengdu, China

OP-04-02 Pathway based genetic markers reveals relation between stroke and Parkinson’s disease
Speaker: Himanshu Narayan Singh, Delhi, India

OP-04-03 A novel co-activation pattern analysis of resting-state fMRI networks in Parkinson’s disease reveals reduced network dynamics that correlate with motor symptom severity
Speaker: Ryan Walsh, Phoenix, United States

OP-04-04 Early Parkinson’s disease is distinguished by a structural network backbone identified through graph theoretical analysis of diffusion MRI
Speaker: Ryan Walsh, Phoenix, United States

OP-04-05 Oligogenic inheritance in Parkinson disease explained by multiple mitochondrial and lysosomal gene mutations
Speaker: Stefanie Smolders, Antwerp, Belgium

OP-04-06 Distinct between-network functional connectivity changes in Parkinson’s disease: A follow-up study
Speaker: Patricia Klobusiakova, Brno, Czech Republic

OP-04-07 Diagnostic utility of a targeted resequencing technique of next generation sequencing in detecting copy number changes in PARK2
Speaker: Yun Joong Kim, Anyang, Republic of Korea
OP-04-08  Investigating glucocerebrosidase (GBA) gene mutations in Parkinson’s disease  
Speaker: Ee Chien Lim, Singapore, Singapore

OP-04-09  Correlations between white matter lesions and cognitive impairment in Parkinson’s disease  
Speaker: Celeste Yan Teng Chen, Singapore, Singapore

OP-04-10  Diagnostic utility of acute levodopa challenge test: Beyond levodopa responsiveness  
Speaker: Mrinal Kumar Acharya, Kolkata, India

OP-04-11  Onset and progression of pathologic atrophy in patients with Huntington disease in Uzbekistan  
Speaker: Farkhod Yunusov, Tashkent, Uzbekistan

OP-04-12  Frontal intermittent rhythmic delta activity (FIRDA) as a marker of Dementia with Lewy Body (DLB). A resting state conventional EEG study  
Speaker: Stefano Calzetti, Parma, Italy

OP-04-13  Comparison of dystonia between Parkinson’s disease and atypical parkinsonism: The clinical usefulness of dystonia distribution and characteristics in the differential diagnosis of parkinsonism  
Speaker: Won Tae Yoon, Seoul, Republic of Korea

OP-04-14  Striato-nigral and cortical 123I-FP-CIT dopaminergic deficits in dementia with Lewy bodies and Parkinson’s disease  
Speaker: Andrea Pilotto, Brescia, Italy

Corporate Session  
12:15 – 13:45  Corporate Session 3: Please see page 77

Plenary Session  
Chair: Maria Stamelou, Athens, Greece

13:45 – 14:15  Developing a Steady Approach to Shaking: The Classification of Tremors  
Speaker: Diego Torres-Russotto, Omaha, United States

14:15 – 14:45  Organizing the Chaotic World of Ataxia  
Speaker: Theresa Zesiewicz, Tampa, United States

14:45 – 15:15  The Unique Spectrum of Pediatric Movement Disorders  
Speaker: Jennifer Friedman, San Diego, United States

Coffee with the Professor  
15:15 – 15:45  Coffee with the Professor 5  
Michael Schwarzschild, Boston, United States
### Parallel Tracks

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 17:15</td>
<td><strong>Other Hyperkinetic Disorders</strong></td>
<td>Rupam Borgohain, Hyderabad, India</td>
<td>Auditorium Lumière</td>
</tr>
<tr>
<td>15:45 – 17:15</td>
<td><strong>What’s Old and New in Myoclonus?</strong></td>
<td>John Caviness, Phoenix, United States</td>
<td></td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td><strong>The Evaluation and Treatment of Restless Legs and Periodic Leg Movements of Sleep</strong></td>
<td>William Ondo, Houston, United States</td>
<td></td>
</tr>
<tr>
<td>16:45 – 17:15</td>
<td><strong>The Approach to Paroxysmal Movement Disorders</strong></td>
<td>Eng-King Tan, Singapore, Singapore</td>
<td></td>
</tr>
</tbody>
</table>

### Skills Workshop

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 17:15</td>
<td><strong>Surgical Therapies for Hyperkinetic Disorders</strong></td>
<td>Marie Laure Welter, Paris, France</td>
<td>Forum 1</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td><strong>DBS for Dystonia: Have We Finally Cracked the Code for Outcome Consistency?</strong></td>
<td>Elena Moro, Grenoble, France</td>
<td></td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td><strong>DBS for the Treatment Tremors, Tourette’s and Chorea</strong></td>
<td>Michele Tagliati, Los Angeles, United States</td>
<td></td>
</tr>
<tr>
<td>16:45 – 17:15</td>
<td><strong>Ultrasound and Lesioning Therapies in Movement Disorders</strong></td>
<td>Binit Shah, Charlottesville, United States</td>
<td></td>
</tr>
</tbody>
</table>

### Parallel Tracks

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 17:15</td>
<td><strong>Rare and Misdiagnosed Movement Disorders</strong></td>
<td>Rukmini Mridula Kandadai, Mumbai, India</td>
<td>Forum 2</td>
</tr>
<tr>
<td>15:45 – 16:15</td>
<td><strong>Spotting and Successfully Treating Wilson’s Disease</strong></td>
<td>Peter Hedera, Nashville, United States</td>
<td></td>
</tr>
<tr>
<td>16:15 – 16:45</td>
<td><strong>One Only Sees What One Knows: Recognizing Autoimmune Disorders</strong></td>
<td>Thien T. Lim, George Town, Malaysia</td>
<td></td>
</tr>
<tr>
<td>16:45 – 17:15</td>
<td><strong>The Diverse Spectrum of Metabolic and Infectious Movement Disorders</strong></td>
<td>Yih-Ru Wu, Taoyuan, Taiwan</td>
<td></td>
</tr>
</tbody>
</table>

### Oral Poster Presentation

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Chair</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:45 – 17:15</td>
<td><strong>Oral Poster Session V – Parkinson Disease</strong></td>
<td>Alberto Albanese, Milan, Italy</td>
<td>Foyer Forum</td>
</tr>
<tr>
<td></td>
<td>(4 minutes oral presentations followed by 1 minute Q&amp;A)</td>
<td>Hui-Fang Shang, Chengdu, China</td>
<td></td>
</tr>
<tr>
<td>OP-05-01</td>
<td><strong>Subcortical steps of visual processing are altered in de novo Parkinson’s disease patients</strong></td>
<td>Emmanuelle Bellot, Grenoble, France</td>
<td></td>
</tr>
<tr>
<td>Session</td>
<td>Title</td>
<td>Speaker</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>OP-05-02</td>
<td><strong>Recommendations for the organization of team care in Parkinson’s disease:</strong> Practice-based evidence from 20 expert centers around the world</td>
<td>Danique Radder, Nijmegen, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>OP-05-03</td>
<td><strong>Effect of istradefylline on non-motor symptoms of Parkinson’s disease:</strong> A sub-analysis of a 1-year observational study in Japan (J-FIRST)</td>
<td>Yasushi Shimo, Tokyo, Japan</td>
<td></td>
</tr>
<tr>
<td>OP-05-04</td>
<td><strong>Pain: A marker of prodromal Parkinson disease?</strong></td>
<td>Mrinal Kumar Acharya, Kolkata, India</td>
<td></td>
</tr>
<tr>
<td>OP-05-05</td>
<td><strong>A randomized controlled trial of DA-9701 on gastric motility in patients with Parkinson’s disease</strong></td>
<td>Cheol Min Shin, Seongnam, Republic of Korea</td>
<td></td>
</tr>
<tr>
<td>OP-05-06</td>
<td><strong>Promoter identification and transcriptional regulation of the anti-inflammation gene CD200R1 in Parkinson’s disease</strong></td>
<td>Lu He, Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>OP-05-07</td>
<td><strong>Long-term efficacy and safety of incobotulinumtoxinA treatment for sialorrhoea in Parkinson’s disease and other neurologic conditions</strong></td>
<td>Fernando Pagan, Washington, United States</td>
<td></td>
</tr>
<tr>
<td>OP-05-08</td>
<td><strong>Long-term prognosis and survival of new Parkinson’s disease subtypes</strong></td>
<td>Eduardo De Pablo-Fernández, London, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>OP-05-09</td>
<td><strong>Acute dopaminergic neurotoxicity of alpha-synuclein oligomers is mediated by microglial cells</strong></td>
<td>Noëlle Callizot, Gardanne, France</td>
<td></td>
</tr>
<tr>
<td>OP-05-10</td>
<td><strong>Nonlinearities in outcome-specific hazard of motor and nonmotor long-term complications of Parkinson’s disease</strong></td>
<td>Stéphane Prange, Bron, France</td>
<td></td>
</tr>
<tr>
<td>OP-05-11</td>
<td><strong>Early serotonergic lesion promotes the emergence and severity of motor symptoms in monkeys</strong></td>
<td>Mathilde Millot, Lyon, France</td>
<td></td>
</tr>
<tr>
<td>OP-05-12</td>
<td><strong>Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a phase 3 double-blind, placebo-controlled trial</strong></td>
<td>Rajesh Pahwa, Kansas City, United States</td>
<td></td>
</tr>
<tr>
<td>OP-05-13</td>
<td><strong>Therapeutic potential of a prolyl hydroxylase Inhibitor FG-4592 for Parkinson’s diseases</strong></td>
<td>Yuncheng Wu, Shanghai, China</td>
<td></td>
</tr>
<tr>
<td>OP-05-14</td>
<td><strong>Sodium oxybate for excessive daytime sleepiness and sleep disturbance in Parkinson’s disease: A randomized clinical trial</strong></td>
<td>Fabian Buechele, Zurich, Switzerland</td>
<td></td>
</tr>
</tbody>
</table>
A novel adenosine A2A receptor antagonist KW-6356 in early Parkinson’s disease: A randomized controlled trial for efficacy and safety  
Speaker: Tetsuya Maeda, Morioka, Japan

A novel mGlu4 compound displays anti-parkinsonian and anti-dyskinetic activity in primate models of Parkinson’s disease  
Speaker: Delphine Charvin, Plan-les-Ouates, Switzerland

Efficacy and safety of incobotulinumtoxinA for upper-limb essential tremor in a randomised, double-blind, placebo-controlled trial using kinematics-guided clinical decision support  
Speaker: Mandar Jog, London, Canada

Comparison of botulinum toxin injections in forearm flexor plus extensor muscles versus flexor muscles alone for the treatment of Essential hand Tremor (FLEX ET)  
Speaker: Shnehal Patel, Cleveland, United States

Beyond cerebellar involvement: Abnormal subcortical volumes in essential tremor  
Speaker: Shweta Prasad, Bangalore, India

17:15 – 18:00 Spotlight Debate: Should we worry that pimavanserin might indeed increase mortality amongst Parkinson patients with psychosis?  
supported by Acadia Pharmaceuticals with an unrestricted grant  
Moderator: Karen Frei, Loma Linda, United States

Yes, we should  
Speaker: Daniel Weintraub, Philadelphia, United States

No, we should not  
Speaker: Zoltan Mari, Cleveland, United States

Questions and Answers

18:00 – 20:00 Grand Parade of Movement Disorders  
Chair: Kailash Bhatia, London, United Kingdom  
Chair: Alberto Albanese, Milan, Italy

Video presenters:  
Chloé Laurencin, Lyon, France  
Wael Ibrahim, Cairo, Egypt  
Soaham Desai, Anand, India  
Marie Vidailhet, Paris, France  
Emanuel Flamand-Roze, Paris, France  
Maria Stamelou, Athens, Greece  
Rukmini Mridula Kandadai, Mumbai, India  
Thien Thien Lim, George Town, Malaysia  
Jirada Sringean, Bangkok, Thailand

Time for Questions and Answers will follow presentation of each video case.
4TH INTERNATIONAL CONGRESS ON TREATMENT OF DYSTONIA

2019

HANNOVER - GERMANY

8 – 11 May

Hannover Congress Centrum

Save the Date

www.treatment-of-dystonia.org
### WEDNESDAY, 22 AUGUST 2018

<table>
<thead>
<tr>
<th>Room</th>
<th>Auditorium Lumière</th>
<th>Forum 1</th>
<th>Forum 2</th>
<th>Foyer Forum</th>
<th>Exhibition Forum 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 – 10:00</td>
<td></td>
<td>Diagnostic and Therapeutic Updates – The Most Promising Diagnostic Tools and Therapies in Movement Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 – 10:30</td>
<td></td>
<td></td>
<td>Coffee Break</td>
<td></td>
<td>Coffee with the Professor</td>
</tr>
<tr>
<td>10:30 – 11:30</td>
<td></td>
<td>Controversies in Movement Disorders – Debating Scientific and Practical Issues</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 – 12:30</td>
<td></td>
<td>Parkinsonism and Related Disorders Journal: Special Session and Awards</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Plenary Session

**08:00 – 10:00**

**Diagnostic and Therapeutic Updates – The Most Promising Diagnostic Tools and Therapies in Movement Disorders**
Chair: Stephane Thobois, Lyon, France  
Chair: Elena Moro, Grenoble, France

- **08:00 – 08:30**
  - **A Peek into the Next Generation of Diagnostic Tools in Movement Disorders**
  Speaker: Jon Stoessl, Vancouver, Canada

- **08:30 – 09:00**
  - **Therapeutic Update I: Where Are We in PD Neuroprotection?**
  Speaker: Tanya Simuni, Chicago, United States

- **09:00 – 09:30**
  - **Therapeutic Update II: The Next Chapter in Symptomatic PD Treatment**
  Speaker: Hubert Fernandez, Cleveland, United States

- **09:30 – 10:00**
  - **Therapeutic Update III: Where are Surgical Therapies Headed in Movement Disorders?**
  Speaker: Joachim Krauss, Hannover, Germany
Coffee with the Professor 6

Marie Vidailhet, Paris, France

Controversies in Movement Disorders – Debating Scientific and Practical Issues

Chair: Alessandro Di Rocco, New York, United States
Chair: Erik Ch. Wolters, Amsterdam, Netherlands

Do Inflammation and Immunity Play an Important Role in PD Pathogenesis?
Pro: Yes, inflammation and immunity play an important role in PD pathogenesis
Dennis Dickson, Jacksonville, United States
Con: No, inflammation and immunity do not play an important role in PD pathogenesis
Etienne Hirsch, Paris, France

Is Genetic Testing Under Utilized in PD and Other Movement Disorders?
Pro: Yes, genetic testing is under-utilized in PD and other movement disorders
Vincenzo Bonifati, Rotterdam, The Netherlands
Con: No, genetic testing is not under-utilized in PD and other movement disorders
Andreas Puschmann, Lund, Sweden

Parkinsonism and Related Disorders Journal: Special Session and Awards

Chair: Vincenzo Bonifati, Rotterdam, Netherlands
Chair: Hubert Fernandez, Cleveland, United States

Update on Parkinsonism and Related Disorders
Speaker: Hubert Fernandez, Cleveland, United States
Speaker: Vincenzo Bonifati, Rotterdam, Netherlands

Best Basic/Translational Science Articles published in PRD
Speaker: Andreas Puschmann, Lund, Sweden

Best Clinical Science Articles Published in PRD
Speaker: Eng-King Tan, Singapore, Singapore

Best Poster Awards
Speaker: Peter Riederer, Wuerzburg, Germany

Closing Words and Announcing Montreal 2019
XXIV WORLD CONGRESS ON PARKINSON’S DISEASE AND RELATED DISORDERS
MONTREAL / CANADA

SAVE THE DATE
2019 16 – 19 June

www.iaprd-world-congress.com

Photo credit: Sebastien Lemyre
**Topic: Basic Neuroscience**

**Forum 3**

**P 002**  
**Lead acute intoxication alters dopaminergic system and locomotor performance in Meriones shawi**  
*Tamegart L.*, **Bouyatas M.M.**, **Abbaoui A.**, **Gamrani H.**  
1Cadi Ayyad University, Biology, Marrakech, Morocco, 2Cadi Ayyad University, Marrakesh, Morocco

**P 009**  
**L-theanine recues quinolinic acid induced motor dysfunction and striatal neurotoxicity: Reduction in oxido-nitrosative stress and restoration of striatal neurotransmitters level**  
*Jamwal S.*, **Kumar P.**  
1SPES, Baddi University of Emerging Sciences and Technologies, Pharmacology, Baddi, India, 2MRS Punjab Technical University, Department of Pharmaceutical Sciences and Technology, Bathinda, India

**P 010**  
**Intranigral inoculation of Parkinson’s disease linked mutation G51D alpha-synuclein fibrils induces Lewy-like pathology in mice**  
1Osaka University, Department of Neurology, Osaka, Japan, 2Osaka University, Department of Neurotherapeutics, Osaka, Japan, 3Niigata University, Department of Molecular Genetics, Niigata, Japan

**P 011**  
**Role of metformin in diabetic aging female rat brain: A future therapy for neurodegenerative diseases**  
*Kumar P.*, **Baquer N.**  
1Jawaharlal Nehru University, School of Life Sciences, New Delhi, India

**P 012**  
**Aloe arborescens and Curcuma longa protect against acute copper exposure induced the neurobehavioral characteristics of Parkinson’s disease in rats**  
*Abbaoui A.*  
1Cadi Ayyad University, Faculty of Sciences Semlalia Marrakech

**P 013**  
**Impaired dopaminergic and serotonergic innervations in thioacetamide induced acute hepatic encephalopathy may be linked to hypolocomotion**  
*El Khiat A.*  
1Cadi Ayyad University, Faculty of Sciences semlalia Marrakech

**P 014**  
**Study on the operation time of deep brain stimulation for Parkinson’s disease**  
*Guo Q.*  
1The First Affiliated Hospital of Sun Yat-sen University

**P 015**  
**2014-2016 worldwide bibliometric snapshot of the scientific literature on Parkinson’s disease**  
1Hôpital Bretonneau, Paris, France, 2Hôpital Corentin Celton, Issy-les-Moulineaux, France, 3Université Paris Descartes, Paris, France, 4Glaxo, Saint Germain sous Doue, France, 5School of Information Systems, Technology and Management, University of New South Wales, UNSW, Sydney, Australia, 6Université Paris Descartes, Faculté de Chirurgie Dentaire, Montrouge, France, 7Hôpital Bretonneau, HUPNVS, AP-HP, Paris, France

**P 017**  
**Clinical correlations between Parkinson’s disease and vascular parkinsonism: New retrospective review from Uzbekistan**  
*Umarov A.*, **Rakhimbaeva G.**  
1Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan

**P 020**  
**The role of apoproteins in the development of Parkinson’s disease**  
*Azizova D.*  
1Tashkent Medical Academy, Medical Biochemistry, Tashkent, Uzbekistan
P 021 Combined administration of an A2A receptor antagonist and a 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease
Costa G., Serra M., Morelli M., Pinna A.
1University of Cagliari, Monserrato, Italy, 2National Institute of Neuroscience, Cagliari, Italy, 3National Research Council of Italy, Institute of Neuroscience, Cagliari, Italy

P 022 Prevention of Parkinson’s disease using natural biological additives
Azizova D., Sobirova R.
1Tashkent Medical Academy, Medical Biochemistry, Tashkent, Uzbekistan, 2Tashkent Medical Academy, Tashkent, Uzbekistan

Topic: Imaging, Genetics and Biomarkers

P 023 Cerebral microbleeds in dementia with Lewy bodies is not characteristic
Polikova T.
1Russian Medical Academy for PostGraduated Education, Neurology, Belgorod, Russian Federation

P 026 Evaluation of the 70 kDa heat shock protein (Hsp70) plasma level in Parkinson’s disease and GBA-associated Parkinson’s disease patients
Senkevich K., Miliukhina I., Gracheva E., Berkovich O., Pchelina S., Multhoff G., Shevtsov M.
1Institute of Experimental Medicine, Saint-Petersburg, Russian Federation, 2Petersburg Nuclear Physics Institute named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Saint-Petersburg, Russian Federation, 3First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation, 4Klinikum rechts der Isar, Technical University of Munich (TUM), Munich, Germany, 5Institute of Cytology of the Russian Academy of Sciences (RAS), Saint-Petersburg, Russian Federation

P 027 A rare fatal Familial parkinsonism in elderly with early respiratory failure
Krishnan P., Sarma G.R.K., Murgod U., Roy A.K., Srinivas M.
1Manipal Hospital, Neurology, Bangalore, India, 2St Johns Medical College and Research Centre, Neurology, Bangalore, India

P 029 Application of convolutional neural networks in the diagnosis of Parkinson’s disease dementia based on magnetic resonance imaging
Binczyk F., Suwalska A., Kocot S., Siuda J., Bobek-Billewicz B.W., Tarnawski R., Polanska J., Rudzinska-Bar M.
1Silesian University of Technology, Faculty of Automatic Control, Electronics and Computer Science, Gliwice, Poland, 2Medical University of Silesia, School of Medicine in Katowice, Department of Neurology, Katowice, Poland, 3Oncology Center - Maria Skłodowska-Curie Institute, Branch in Gliwice, Department of Radiology and Diagnostic Imaging, Gliwice, Poland, 4Oncology Center - Maria Skłodowska-Curie Institute, Branch in Gliwice, III Department of Radiotherapy and Chemotherapy, Gliwice, Poland

P 030 DAT scan abnormalities in juvenile Westphal variant of Huntington’s disease
Pedouim F., Dashtipour K., Frei K.
1Loma Linda University, Neurology, Loma Linda, United States

P 031 Influence of alpha-synuclein promoter (Rep1) polymorphism on cognition, disability and plasma alpha-synuclein levels in Parkinson’s disease
Ng A., Tan J., Zhao Y., Zhenghao L., Ng S., Ng E., Tan E.K., Tan L.
1National Neuroscience Institute, Neurology, Singapore, Singapore, 2Singapore General Hospital, Research, Singapore, Singapore
P 032 The role of 18F-FP-CIT PET in differentiation of progressive supranuclear palsy and frontotemporal dementia in the early stage
Lee P.H.1, Yoo H.S.1, Chung S.J.1, Sohn Y.H.1
1Yonsei University College of Medicine, Department of Neurology, Seoul, Republic of Korea

P 034 Association analysis of DRD2 rs2283265 and DRD1 rs4532 with Parkinson’s disease and multiple system atrophy in a large Chinese population
Gu X.1, Chen Y.1, Cao B.1, Ou R.1, Zhang L.1, Hou Y.1, Wei Q.1, Song W.1, Shang H.1
1West China Hospital, Sichuan University, Department of Neurology, Chengdu, China

P 035 Early brain metabolic changes in patients with Parkinson’s disease and its correlation to the risk of falling
Brumberg J.1, Pozzi N.2, Marotta G.3, Buck A.1, Volkmann J.2, Pezzoli G.4, Isaias I.2
1University Hospital Wuerzburg, Nuclear Medicine, Wuerzburg, Germany, 2University Hospital Wuerzburg, Neurology, Wuerzburg, Germany, 3Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Nuclear Medicine, Milan, Italy, 4ASST G. Pini-CTO, Centro Parkinson, Milan, Italy

P 036 Spg 11 gene mutation associated autosomal recessive hereditary spastic paraplegia presenting with partially levodopa responsive parkinsonism, stereotypy and cognitive decline
Desai S.1, Singh S.1, Patel V.2, Sheth J.3
1Pramukhswami Medical College and Shree Krishna Hospital, Neurology, Anand, India, 2Pramukhswami Medical College and Shree Krishna Hospital, Radiology, Anand, India, 3FRIDGE HOUSE, Genetics, Ahmedabad, India

P 037 Gene-lifestyle interactions in Parkinson’s disease
Chen C.Y.T.1, Ong Y.L.1, Deng X.1, Li H.H.3, Ng E.1, Kumar P.M.1,2, Au W.L.1, Ratnagopal P.1,2, Tan L.1, Tan E.K.1,2
1National Neuroscience Institute, Neurology, Singapore, Singapore, 2Duke-NUS Graduate Medical School, Singapore, Singapore, 3Singapore General Hospital, Health Services Research, Singapore, Singapore
**Topic: Deep Brain Stimulation and Functional Neurosurgery**

**P 040**

*Improvement of apraxia of eyelid opening in a patient with Parkinson’s disease following the change of the directional lead for subthalamic nucleus deep brain stimulation*

*Kadowaki T.*, *Hamaguchi M.*, *Shiina T.*, *Shingo T.*, *Sakuramoto H.*, *Suzuki K.*, *Hirata K.*

1Dokkyo Medical University, Department of Neurology, Mibu, Japan, 2Dokkyo Medical University, Department of Neurosurgery, Mibu, Japan

**P 041**

*Toe dystonia in Parkinson’s disease: Impact of subthalamic nucleus deep brain stimulation*

*Laurencin C.*, *Montaut S.*, *Danaila T.*, *Mertens P.*, *Vial C.*, *Thobois S.*

1Hopital Neurologique Pierre Wertheimer, Lyon, France, 2Institut des Sciences Cognitives, Bron, France

**P 042**

*Long term outcome of the subthalamic nucleus DBS for advanced Parkinson’s disease: An eight years follow-up study in China*

*Guo Q.*

1The First Affiliated Hospital of Sun Yat-sen University

**P 043**

*The long-term development of excessive daytime sleepiness after subthalamic deep brain stimulation in patients with Parkinson’s disease*


1Daegu St.Mary’s Hospital, The Catholic University of Korea, Neurology, Daejeon, Republic of Korea, 2Movement Disorder Center, Seoul National University Hospital, Parkinson Study Group, Seoul National University, Neurology, Seoul, Republic of Korea, 3Nowon Eulji Medical Center, Eulji University, Neurology, Seoul, Republic of Korea

**P 044**

*Usefulness of directional deep brain stimulation in patients with movement disorders*

*Contreras Pinto M.*, *Saavedra J.S.*, *Roldan P.*, *Muñoz E.*, *Rumia J.*, *Vallderiola F.*

1Hospital Clinic - Universidad de Barcelona, Barcelona, Spain

**P 045**

*Predicting patient discharge disposition subsequent to deep brain stimulation surgery: A pilot study*

*Farrokhi F.*

1Virginia Mason, Neurosurgery, Seattle, United States

**P 046**

*Meta-analysis of mortality following subthalamic and pallidal deep brain stimulation for patients with Parkinson’s disease*

*Negida A.*, *Shalash A.*

1School of Medicine, Zagazig University, Zagazig, Egypt, 2Ain Shams University, Parkinson’s disease and Movement Disorders Unit, Cairo, Egypt

**Topic: Parkinson Disease**

**P 047**

*Evaluation of genetic changes of polymerase chain reaction in patients with PD in early stage*

*Salohiddinov M.*

1Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan
P 050 Influence of the stage in Parkinson’s Disease on the level of cognitive impairment in people over 65 years of age
Mollinedo Cardalda I.1, Resúa B.2, Díaz-Pacheco C.3, Millán-Calenti J.4, Cancela J.M.2
1University of Vigo, Research group HealthyFit, Institute of Health Research Galicia Sur (IISGS), Hospital University Complex of Pontevedra (CHOP), SERGAS, Vilagarcía de Arousa, Spain, 2University of Vigo, Research group HealthyFit, Institute of Health Research Galicia Sur (IISGS), Hospital University Complex of Pontevedra (CHOP), SERGAS, Pontevedra, Spain, 3Asociación Provincial de Parkinson, Pontevedra, Spain, 4University of A Coruña, Gerontological Research Group, Biomedical Research Institute of A Coruña (INIBIC), Hospital University Complex of A Coruña (CHUAC), SERGAS, A Coruña, Spain

P 056 Use of safinamide in Parkinson’s disease patients over 70 years with dyskinesias and pharmacological psychosis
Rodríguez-Sanz A.1, Mascias Cadavid J.1, Vivancos Matellano F.1
1Hospital Universitario La Paz, Madrid, Spain

P 058 A non-motor symptom unheard of? Hearing loss in Mexican patients with Parkinson’s disease
Castillo Torres S.A.1, Cerda-Contreras C.1, Soto Galindo G.A.2, Estrada-Bellmann I.1, Treviño-González J.L.2
1Universidad Autónoma de Nuevo León, Servicio de Neurología, Monterrey, Mexico, 2Universidad Autónoma de Nuevo León, Centro Universitario de Otorrinolaringología y Cirugía de Cabeza y Cuello, Monterrey, Mexico

P 059 Development of anti-Parkinsonism poly herbal sustained release formulation composed of potential traditional plant extracts
Jain A.1, Jain S.2, Bhargav S.3
1Bhagyoday Tirth Pharmacy College, Pharmacy, Sagar, India, 2Bhagyoday Tirth Pharmacy College, Sagar, India, 3United Institute of Pharmacy, Allahabad, India

P 060 Microarray analysis upon a synthetic α-synuclein induced model reveals some susceptibility genes in Parkinson’s disease
Tao E.1
1The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Department of Neurology, Guangzhou, China

P 061 Postural instability in patients with Parkinson disease and its correction by balance therapy
Akbarkhodjaeva Z.1, Rakhimbaeva G.1, Saidvaliev F.1
1Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan

P 062 Insomnia due to restlessness restricted to the perianal region in a patient with Parkinson’s disease
Okamura M.1, Suzuki K.1, Hirata K.1
1Dokkyo Medical University, Neurology, Tochigi, Japan

P 063 Worsening of dyskinesia following the change of peptic ulcer treatment in a patient with Parkinson’s disease under the levodopa-carbidopa intestinal gel infusion therapy
Sakuramoto H.1, Kadowaki T.1, Tomohiko S.1, Fujita H.1, Suzuki K.1, Hirata K.1
1Dokkyo Medical University, Kitakobayashi, Mibu, Tochigi, Japan

P 064 Investigation of sleep duration, sedentary behavior, and physical activity in idiopathic Parkinson disease
Aktar B.1, Donmez Colakoglu B.2, Balci B.1
1Dokuz Eylul University School of Physical Therapy and Rehabilitation, Izmir, Turkey, 2Dokuz Eylul University, Department of Neurology, Izmir, Turkey
Measurement of Parkinson’s disease patients functional ability before and after physiotherapy: A case series

Cousins J.1, Lindahl A.2, Leighton N.2
1Warwick Medical School, Coventry, United Kingdom, 2University Hospital Coventry and Warwickshire, Coventry, United Kingdom

Rotenone induced Parkinson’s disease model: Analysis of PARK2 and PINK1 genes expression

Abdul Razzak Z.1,2, Abbas G.1, Rafi K.1,2, Usman Simjee S.1,2
1International Center for Chemical and Biological Sciences (ICCBS), H.E.J. Research Institute of Chemistry, Karachi, Pakistan, 2International Center for Chemical and Biological Sciences (ICCBS), Dr. Panjwani Center for Molecular Medicine and Drug Research, Karachi, Pakistan

The late effects of traumatic brain injury – leading to Parkinson disease – a prospective study

Fatima A.1, Zaidi S.S.A.2
1Singapore General Hospital, Lahore, Pakistan, 2Wecare Medical Centre, Lahore, Pakistan

Is restless legs syndrome (RLS), a prodromal feature of Parkinson’s disease (PD), associated to small fiber pathology?

Calzetti S.1, Bellanova M.F.2, Saccani E.2, Negrotti A.1, Capozzi A.2, Pietrini V.2
1Neurology Unit Azienda Ospedaliero-Universitaria of Parma, Parma, Italy, 2Neuropathology Lab Azienda Ospedaliero-Universitaria of Parma, Parma, Italy

Does the side of onset of motor symptoms in parkinsonian patients have an impact on the global clinical phenotype?

Lazzeri G.1, Franco G.1, Trezzi I.1, Borelli L.2, Monfrini E.1, Frattini E.1, Ardolino G.2, Cogiamanian F.2, Di Fonzo A.1
1IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Center, Neuroscience Section, Department of Pathophysiology and Transplantation, University of Milan, Milano, Italy, 2IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, U.O. Neurofisiopatologia, Milano, Italy

Instrumental evaluation of autonomic nervous system dysfunction in idiopathic Parkinson’s disease

Doregowska M.1, Toś M.2, Malkiewicz J.2, Kaczmarczyk A.1, Siuda J.1, Rudzińska-Bar M.1
1Medical University of Silesia, Department of Neuroradiology, Katowice, Poland, 2Medical University of Silesia, Students Scientific Association, Katowice, Poland

Effective rehabilitation program for Parkinson’s disease – from National Hospital Organization Japan

Hasegawa K.1, NHO TSPD Study Group
1National Hospital Organization, Sagamihara National Hospital, Neurology, Sagamihara, Japan

Interrelation between chronic pain syndrome and cognitive and affective disturbances in patients with Parkinson’s disease

Stepanchenko K.1
1Kharkiv Medical Academy of Postgraduate Education, Department of Neurology, Kharkiv, Ukraine

Effect of ventricle size on development of freezing of gait in Parkinson’s disease

Lee J.1
1Inje University, Neurology, Goyang-si, Republic of Korea

Non-motor symptoms of Parkinson’s disease: Evaluation of urinary disorders

Karbozova K.1
1Kyrgyz State Medical Academy, Neurology and Clinical Genetics Department, Bishkek, Kyrgyzstan
P 082  The impact of levodopa induced dyskinesia on the quality of life in Parkinson’s disease patients  
Prakash K.M.1, Lim E.-C.1, Nadkarni N.2, Lye W.-K.3, Tan E.-K.1  
1National Neuroscience Institute, Singapore, Singapore, 2Duke NUS Medical School, Centre of Quantitative Medicine, Singapore, Singapore

P 083  Prevalence and associations for depression in patients with Parkinson’s disease: A Sri Lankan experience  
Herath T.1  
1National Hospital of Sri Lanka, Kandy, Sri Lanka

P 085  Metabolic and functional changes in the eye as a manifestation of the systemic neurodegeneration at parkinsonism  
Kim A.1, Pavlenko T.2, Pavlova E.1, Chesnokova N.2, Ugrumov M.1,3  
1Koltsov Institute of Developmental Biology of Russian Academy of Sciences, Moscow, Russian Federation, 2Helmholtz Moscow Research Institute of Eye Diseases of Ministry of Health of the Russian Federation, Moscow, Russian Federation, 3National Research University Higher School of Economics, Moscow, Russian Federation

P 086  Acute lethargic state after abrupt apomorphine withdrawal in Parkinson’s disease  
Cavallieri F.1,2, Fraix V.2,3,4, Meoni S.2,3,4, Krack P.5, Moro E.2,3,4, Castrioto A.2,3,4  
1St. Agostino-Estense Hospital, University of Modena and Reggio Emilia, Department of Neuroscience, Modena, Italy, 2CHU de Grenoble, Movement Disorders Unit, Neurology Department, Grenoble, France, 3Univ. Grenoble Alpes, Grenoble Institut des Neurosciences, Grenoble, France, 4Inserm, U1216, Grenoble, France, 5Faculty of Medicine, University of Geneva, Department of Clinical Neurosciences (Neurology), Geneva, Switzerland

P 089  Evaluations of additive effect of two indigenous medicinal plants Cedrus Deodara and Mucuna pruriens towards the treatment of Parkinson’s disease  
Jain S.1, Jain A.1, Bhargav S.2  
1Bhagyoday Tirth Pharmacy College, Pharmacy, Sagar, India, 2United Institute of Pharmacy, Pharmacy, Allahabad, India

P 090  ON is not always ON: When non-motor fluctuations do not match motor fluctuation conditions  
Del Prete E.1,2, Schmitt E.1, Meoni S.1, Fraix V.1, Castrioto A.1, Pelissier P.1, Ceravolo R.2, Moro E.1  
1Movement Disorders Unit, Division of Neurology, CHU Grenoble, Grenoble Alpes University, INSERM1216, Grenoble, France, 2Department of Clinical and Experimental Medicine, Neurology Unit, University of Pisa, Pisa, Italy

P 091  Trunk exercise program for Parkinson’s disease  
Cheon S.-M.1, Kim J.W.1  
1Dong-A University School of Medicine, Neurology, Busan, Republic of Korea

P 092  The neuropsychiatric fluctuations scale for Parkinson’s disease: A pilot study  
Schmitt E.1  
1C.H.U de Grenoble, Neurology, Movement Disorders, Grenoble Cedex, France

P 093  The impact of impulsivity on quality of life in drug-naive Parkinson’s disease  
Ryu D.-W.1, Kim J.-S.1  
1Catholic University, Neurology, Seoul, Republic of Korea

P 094  The cost-effectiveness of specialized nursing interventions for people with Parkinson’s disease: protocol of a randomized controlled trial  
Radder D.1,2, de Vries N.1,2, Lennaerts H.3, Munneke M.1,2, Bastiaan B.1,2  
1Radboud University Medical Center, Department of Neurology, Nijmegen, Netherlands, 2Donders Institute for Brain, Cognition and Behaviour, Nijmegen, Netherlands, 3Radboud University Medical Center, Department of Anaesthesiology, Pain and Palliative Care, Nijmegen, Netherlands
P 095 Clinical features of Parkinson’s disease with and without rapid eye movement sleep behavior disorder
1Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, United States, 3Department of Neurology, Methodist Hospital, Houston, United States

P 096 Investigation to expand application sites of rotigotine transdermal patch
Kujirai H., Aoyama N., Abe K., Takahashi M., Inaba A., Orimo S.
1Kanto Central Hospital, Neurology, Setagaya-ku, Japan

P 097 The polymorphism of SREBF1 Gene rs11868035 G/A is associated with susceptibility to Parkinson’s disease in a Chinese population
Lou F., Li M.
1First Affiliated Hospital of China Medical University, Shenyang, China, 2The Fourth Affiliated Hospital of China Medical University, Shenyang, China

P 098 Quantitative keyboard measurement correlates with changes in subthalamic nucleus LFPs of Parkinson’s disease patients treated with dopaminergic medication better than UPDRS subscores
Ozturk M., Abosch A., Francis D., Wu J., Jimenez-Shahed J., Ince N.F.
1University of Houston, Houston, United States, 2University of Colorado, Aurora, United States, 3Medtronic, Minneapolis, United States, 4Baylor College of Medicine, Houston, United States

P 100 Brain-derived neutrophic factor and lipid profile in Parkinson’s disease
Alomari M., Khalil H., Khabour O.
1Jordan University of Science and Technology, Rehabilitation Sciences, Irbid, Jordan, 2Jordan University of Science and Technology, Rehabilitation Sciences, Irbid, Jordan

P 101 Fatigue in Parkinson’s disease: Correlates and its effects on ability of daily living
1Dongguan People’s Hospital, Dongguan, China, 2Guangdong Medical University, Dongguan, China

P 103 Thai bamboo dance: Improvements in gait, balance and foot clearance for Parkinson’s disease
Khongprasert S., Wangyapongsataporn K., Bhidayasiri R.
1Chulalongkorn University, Faculty of Sports Science, Bangkok, Thailand, 2Chulalongkorn Center of Excellence for Parkinson’s disease and Related Disorders, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

P 104 Effectiveness and safety of continuous infusion of levodopa-carbidopa intestinal therapy for patients with advanced Parkinson’s disease: A single center experience
Vuletic V.
1University Hospital Centre Rijeka, Medical Faculty Rijeka, Department of Neurology, Rijeka, Croatia

P 106 Russian validation study of the Berg balance scale
Zimin A., Yusupova D.
1Research Center of Neurology, Moscow, Russian Federation
P 107 Assessing Tele-Health Outcomes in Multiyear Extensions of Parkinson’s Disease trials (AT-HOME PD): Design of a long-term observational study
1Northwestern University Feinberg School of Medicine, Neurology, Chicago, United States, 2University of Rochester, Rochester, United States, 3Sage Bionetworks, Seattle, United States, 4Michael J Fox Foundation, New York, United States, 5Massachusetts General Hospital, Boston, United States

P 108 Neuroprotective effect of Naringin loaded solid lipid nanoparticles via induction of GDNF in MPP+ induced Parkinson’s disease in animal model
Rahman M.1,2, Kumar V.2
1Shaalom Institute of Health and Sciences, SHIATS, Pharmaceutical Sciences, Allahabad, India, 2Sam Higginbottom University of Agriculture, Technology & Sciences (SHUATS), Pharmaceutical Sciences, Allahabad, India

P 109 Decreased striatal dopamine and neuropsychiatric symptoms in patients with Parkinson’s disease
Lim E.1, Oh Y.1, Kim J.1
1Department of Neurology, College of Medicine, The Catholic University of Korea, Neurology, Seoul, Republic of South Korea

P 110 Patterns of movement disorders among HIV/AIDS patients: A cross sectional study
Belay L.1
1Ethiopian Federal Police Commission Referral Hospital, Neurology, Addis Ababa, Ethiopia

P 111 Unraveling gut microbiota in Parkinson’s disease and atypical parkinsonism
1Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 2ASST G. Pini-CTO, ex ICP, Parkinson Institute, Milano, Italy, 3Institute of Biomedical Technologies, Italian National Research Council, Milano, Italy, 4Istituto Auxologico Italiano, IRCCS, San Michele Hospital, Experimental Research Laboratory on Obesity, Milano, Italy, 5Ospedale Classificato Moriggia Pelascini di Gravedona, Dipartimento Riabilitazione Malattia di Parkinson e Disturbi del Movimento, Gravedona, Italy

P 112 A phase 2A study of nilotinib in patients with advanced and early Parkinson’s disease study design
1Northwestern University Feinberg School of Medicine, Neurology, Chicago, United States, 2The Michael J Fox Foundation, New York, United States, 3TransThera Consulting Co., Portland, United States, 4University of Iowa, Iowa City, United States, 5The Cure Parkinson’s Trust, London, United Kingdom, 6Van Andel Research Institute, Grand Rapids, United States, 7Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, United States, 8Massachusetts General Hospital, Charlestown, United States, 9Lumos Pharma Consultant, Austin, United States, 10University of Rochester, Rochester, United States, 11Parkinson’s Disease Patient Research Advocate, Marlboro, United States

P 113 The comparison of gut biogeography of the gut bacterial microbiota in Parkinson’s disease
Hirayama M.1, Ito M.2, Minato T.1, Maeda T.2, Ohno K.2
1University Graduate School of Medicine, Department of Pathophysiological Laboratory Sciences, Nagoya, Japan, 2Nagoya University Graduate School of Medicine, Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya, Japan, 3School of Medicine, Iwate Medical University, Department of Internal Medicine, Morioka, Japan
POSTER EXHIBITION

P 114 Clinical correlation of serum insulin-like growth factor-1 levels in patients with Parkinson’s disease and related disorders
Suzuki K.1, Kadokwai T.1, Fujita H.1, Watanabe Y.1, Matsubara T.1, Suzuki S.1, Ishii Y.1, Okamura M.1, Shiina T.1, Sakuramoto H.1, Hamaguchi M.1, Matsubara M.1, Hirata K.1
1Dokkyo Medical University, Department of Neurology, Tochigi, Japan

P 115 Serum uric acid is associated with cognitive decline in de novo patients with Parkinson’s disease
Baik J.S.1, Ma H.I.2, Han S.W.1
1Sanggye Paik Hospital / Inje University, Department of Neurology, Seoul, Republic of South Korea, 2Saged Heart Hospital / Hallym University, Department of Neurology, Anyang-si, Republic of South Korea

P 116 Home mobility system for monitoring patients with Parkinson’s disease: Validation with actigraphy
Shin C.1, Ahn T.-B.1
1Kyung Hee University Hospital, Seoul, Korea, Republic of South Korea

P 118 Can coenzyme Q10 and creatine slow the progress of Parkinson’s disease?
Negida A.1, Shalash A.2
1School of Medicine, Zagazig University, Zagazig, Egypt, 2Ain Shams University, Parkinson’s Disease and Movement Disorders Unit, Cairo, Egypt

P 119 Carrier mediated delivery system bearing dopamine for effective management of parkinsonism
Bhargava S.1, Bhargava V.2
1Himalayan University, Kanpur, India, 2GTB Hospital, Kanpur, India

P 120 A phase 3 study of isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update
1Northwestern University Feinberg School of Medicine, Neurology, Chicago, United States, 2University of Rochester, Neurology, Rochester, United States, 3University of Rochester, Rochester, United States, 4National Institute of Neurological Disorders and Stroke, Bethesda, United States

P 121 Neuropsychiatric and behavior changes in Parkinson’s disease patients with impulse control disorder after switching-off dopamine agonist by levodopa/carbidopa slow-release formulations
Lee J.-Y.1, Cho J.2, Jeon B.3, Koh S.-B.4, Yoon W.T.5, Kim J.W.6, REIN-PD investigators
1Seoul National University-SMG Boramae Medical Center, Neurology, Seoul, Republic of Korea, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Neurology, Seoul, Republic of Korea, 3Seoul National University College of Medicine, Neurology, Seoul, Republic of Korea, 4Korea University Guro Hospital, Seoul, Republic of Korea, 5KangBok Samsung Hospital, Sungkyunkwan University College of Medicine, Neurology, Seoul, Republic of Korea, 6Dong-A University School of Medicine, Seoul, Republic of Korea

P 122 Microstructural changes in white and grey matter related to apathy, depression and anxiety in de novo Parkinson’s disease patients
Prange S.1, Metereau E.1, Maillet A.1, Lhomme E.2, Klinger H.3, Pelissier P.2, Ibarrola D.4, Heckmann R.A.5, Broussolle E.6, Castrioto A.2, Tremblay L.1, Sambato V.1, Krack P.6, Thobois S.3
1CNRS, Institut des Sciences Cognitives, Physiopathology of basal ganglia, UMR 5229, Bron, France, 2Université de Grenoble, Grenoble Institut des Neurosciences, Grenoble, France, 3Hôpital Neurologique Pierre Wertheimer, Centre expert Parkinson, Bron, France, 4CERMEP, Bron, France, 5University of Gothenburg, MedTech West, Sahlgrenska University Hospital, Gothenburg, Sweden, 6Hôpitaux Universitaires de Genève, Service de Neurologie, Genève, Switzerland
P 123  Gait patterns in Parkinson’s disease with or without cognitive impairment  
Kim S.¹, Yang Y.¹, Ha S.¹, Han J.H.¹  
¹Veterans Health Service Medical Center, Seoul, Republic of Korea

P 124  Effect of striatal dopamine depletion on cognition in de novo Parkinson’s disease  
Lee P.H.², Baik J.S.², Chung S.J.², Yoo H.S.², Oh J.S.², Kim J.S.², Sohn Y.H.²  
²Yonsei University College of Medicine, Neurology, Seoul, Republic of South Korea, ³Inje University College of Medicine, Neurology, Seoul, Republic of South Korea, ⁴University of Ulsan College of Medicine, Nuclear Medicine, Seoul, Republic of South Korea

P 125  Socio-biological cues and saccade generation in Parkinson’s disease  
Kocoglu K.¹, Colakoglu B.D.², Cakmur R.², Akdal G.², Hodgson T.³  
¹Dokuz Eylul University, Department of Neuroscience, Izmir, Turkey, ²Dokuz Eylul University, Department of Neurology, Izmir, Turkey, ³University of Lincoln, School of Psychology, Lincoln, United Kingdom

P 126  Waking-day patterns of motor complications in Parkinson’s disease and the effect of ADS-5102  
Patni R.¹, Pahwa R.², Tanner C.M.³, Johnson R.¹, Howard R.⁴, Hauser R.A.⁵  
¹Adamas Pharmaceuticals, Inc., Emeryville, United States, ²University of Kansas Medical Center, Kansas City, United States, ³University California San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, United States, ⁴Venical Solutions, Del Mar, United States, ⁵University of South Florida, Tampa, United States

P 128  Effective diagnostic and treatment methods in vascular parkinsonism and Parkinson’s disease: Temporalrhythmal correction  
Akramova D.¹, Rakhimbaeva G.¹, Kuranbaeva S.²  
¹Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan, ²Tashkent Medical Academy, Tashkent, Uzbekistan

P 132  New clinical research: The role of OncoMarkers in Parkinson’s disease and vascular parkinsonism  
Akramova D.¹  
¹Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan

P 134  A randomized, double blind, placebo controlled, single ascending dose, safety and pharmacokinetic/pharmacodynamic study of INP103 in the presence of benzerazide, to L-dopa responsive Parkinson’s patients  
Shrewsbury S.¹, Lehn A.², Satterly K.², Swardstrom M.¹, Hoekman J.³  
¹Impel NeuroPharma, Clinical Development, Seattle, United States, ²Mater Hospital, Brisbane, Australia, ³Impel NeuroPharma, Life Sciences, Seattle, United States

P 135  Spectral fingerprints of impulse control disorders in Parkinson’s disease  
Spay C.¹, Lio G.², Cilia R.³, Ballanger B.¹, Boulinguez P.¹  
¹Centre de Recherche en Neurosciences de Lyon, Bron, France, ²Institut des Sciences Cognitives Marc Jeannerod, Bron, France, ³Parkinson Institute, ASST Gaetano-Pini-CTO, Milan, Italy

P 136  Treatment approaches to pain in Parkinson disease: A systematic review  
Sy M.A.C.¹, Rosales R.¹  
¹Department of Neurology & Psychiatry, Parkinson and Disorders of Movement Center, University of Santo Tomas Hospital, Manila, Philippines

P 137  REM sleep behavior disorder in Parkinson disease: Association with blunted heart rate variability on standing  
Gil Y.E.¹, Yoon J.H.¹  
¹Ajou University Hospital, Department of Neurology, Suwon, Republic of Korea
Efficacy of incobotulinumtoxinA in patients with sialorrhoea, as assessed using the modified Radboud Oral Motor Inventory for Parkinson’s disease (mROMP)

Impact of injection guidance techniques on the efficacy and safety of incobotulinumtoxinA for sialorrhoea

Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from the phase 3 double-blind, placebo-controlled trial
Factor S., Isaacson S., Sciarappa K., Bhargava P., Vakili G., Blum D., Olanow C.W., Navia B.

Opicapone as adjunctive therapy to levodopa in patients with Parkinson’s disease and motor fluctuations: Global impressions of change compared to placebo and entacapone

When PSP and CBD overlap: A case report
Nitu E.-B., Mitrea D.-A.

Topic: Other Parkinsonian Disorders
P 144 Effects of green tea extract on Parkinsonism and related disorders; neuroleptic anxiety syndrome, growth & pain
Malik T, Haleem D.J.1,2,3
1National University of Health Sciences, Basic Sciences, Physiology, Lombard, United States, 2The University of Karachi, Neurochemistry & Biochemical Neuropharmacology Research Laboratory, Department of Biochemistry, Karachi, Pakistan, 3Panjwani Center of Molecular Medicine, ICCBS, Karachi, Pakistan

P 145 Features of the course of Parkinson’s disease in congenital anomalies of cerebral vessels
Norboboev A.1
1Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan

P 147 Pharmacologic approaches in dementia with Lewy bodies: Lessons learned from a case series
Amodeo K.1, Hegeman Richard I.1
1University of Rochester, Neurology, Rochester, United States

P 148 Levosulpride induced persistent movement disorders: Case series
Mehta S.1, Lal V.1
1PGIMER, Neurology, Chandigarh, India

P 149 Single photon emission computer tomography in the differentiation of progressive supranuclear palsy, corticobasal syndrome and multiple system atrophy
Alster P.1, Koziorowski D.1, Królicki L.2, Friedman A.1
1Medical University of Warsaw, Neurology, Warsaw, Poland, 2Medical University of Warsaw, Nuclear Medicine, Warsaw, Poland

P 150 Movement disorders in bilateral striatopallidodentate calcinosis (Fahr’s syndrome): An analysis of 9 patients
Burzhunova M.1, Garabova N.1, Goytemirova P.1
1RUDN University, Moscow, Russian Federation

P 153 Memory enhancing effect of combined alcoholic extract of cedrus ceodara loud and Vitex Nirgundi in scopolamine-induced cognitive impairment in mice
Jain S.1, Jain A.2, Bhargav S.3
1Bhagyoday Tirth Pharmacy College, Pharmacy, Sagar, India, 2Bhagyoday Tirth Pharmacy College, Sagar, India, 3United Institute of Pharmacy, Pharmacy, Allahabad, India

P 154 Characterization of constipation in multiple system atrophy using Rome III diagnostic criteria
Mishima T.1, Fujioka S.1, Inoue K.1, Fukae J.1, Tsuboi Y.1
1Fukuoka University, Neurology, Fukuoka, Japan

P 156 Risk of Parkinson disease associated with prokinetics from Korean National Health Insurance service claims data
1Hallym University College of Medicine, Neurology, Anyang, Republic of Korea, 2Gachon University, Pharmacy, Incheon, Republic of Korea, 3Sanggye Baik Hospital Inje University, Neurology, Seoul, Republic of Korea, 4Jeju National University College of Medicine, Neurology, Jeju, Republic of Korea

P 157 Levodopa-induced dyskinesias impact patient’s quality of life in Parkinson’s disease in Singapore
Lim E.C.1, Nadkarni N.V.2, Lye W.K.2, Prakash K.M.1,2, Tan E.K.1,3
1National Neuroscience Institute, Neurology, Singapore, Singapore, 2DUKE-NUS Graduate Medical School, Centre of Quantitative Medicine, Singapore, Singapore, 3Singapore General Hospital, Department of Neurology, Singapore, Singapore
Relationship of performance in judgment tasks with executive function tasks and theory of mind in patients with Alzheimer’s disease and subjects with mild cognitive impairment

Basante Avendaño R.A., Sosa Ortiz A.L., Acosta Castillo I.
1National Institute of Neurology and Neurosurgery, Psychiatry, Mexico, Mexico, 2National Institute of Neurology and Neurosurgery, Cognitive Aging and Dementias, Mexico, Mexico

Neuroprotective role of 17β estradiol against amyloid beta neurotoxicity in synaptosomes of aging female rats

Kumar P., Baquer N.
1Jawaharlal Nehru University, School of Life Sciences, New Delhi, India

Principles of non-pharmacological therapy in patients with Parkinson’s diseases

Maxamatjanova N.
1Tashkent Medical Academy, Tashkent, Uzbekistan, 2Tashkent Medical Academy, Neurological Diseases, Tashkent, Uzbekistan

Identifying the association of depression and distress in Pakistani patients diagnosed with parkinsonism syndrome

Fatima A., Zaidi S.S.A.
1Sir Ganga Ram Hospital, Lahore, Pakistan, 2Wecare Medical Centre, Lahore, Pakistan

Features of cognitive functions in parkinsonism

Tolibov D., Rakhimbaeva G.
1Tashkent Medical Academy, Tashkent, Uzbekistan

The views of adults with Huntington’s disease on assisted dying in Uzbekistan: A qualitative exploration

Yunusov F., Rakhimbaeva G.
1Tashkent Medical Academy, Tashkent, Uzbekistan

Cognitive dysfunction in multiple system atrophy-C

Han J.H., Yang Y.S.
1Veterans Health Service Medical Center, Department of Neurology, Seoul, Republic of South Korea

Assessment of cognitive disorders in Parkinson’s disease (PD)

Tolibov D., Rakhimbaeva G.
1Tashkent Medical Academy, Tashkent, Uzbekistan

New assessments of cognitive disorders in patients with parkinsonism in Uzbekistan

Umarov A., Rakhimbaeva G., Rakhimova S.
1Tashkent Medical Academy, Department of Neurology, Tashkent, Uzbekistan
**Topic: Dystonia / Tremors**

**P 172**  
Bilateral pallidotomy in patients with generalized dystonia in Uzbekistan  
*Nosirjonov M.*  
1Tashkent Medical Academy, Tashkent, Uzbekistan

**P 173**  
Sensorimotor plasticity in writer’s cramp parallels clinical improvement after botulinum toxin injections  
*Fournier M.*,  
1CHU Grenoble Alpes, La Tronche, France,  
2Grenoble Institute of Neurosciences, Grenoble, France,  
3Université Grenoble Alpes, BSHM, Saint Martin d’Hères, France,  
4Universidade Federal do Rio Grande do Norte, Departamento de Medicina Integrada, Natal, Brazil,  
5LPCN - CNRS UMR 5105 | IRMaGe - CNRS UMS 3552, Université Grenoble Alpes, BSHM, Grenoble, France,  
6Campus Biotech - UPHUMMEL, Rm H4-03 194.084, Brain Mind Institute, SV, Ecole Polytechnique Fédérale de Lausanne (EPFL), Genève, Switzerland,  
7CHU Grenoble Alpes, Movement Disorders Unit, Division of Neurology, CHU of Grenoble, Grenoble, France,  
8Université Grenoble Alpes, Grenoble, France

**P 175**  
Ultrasound echogenicity of the nuclei raphe as marker of depressive disorders in the cervical dystonia  
*Krzak-Kubica A.*,  
1Medical University of Silesia, Department of Neurology, Katowice, Poland,  
2Medical University of Silesia, Department of Biophysics, Katowice, Poland

**P 176**  
Orthostatic tremor complicated by spinal cord schwannoma  
*Kim H.S.*,  
1Bundang CHA Medical Center/ CHA University, Neurology, Bundang-gu, Republic of Korea

**Topic: Chorea, Athetosis and Ballism**

**P 179**  
Case report: Chorea gravidarum persisting after delivery  
*Frei K.*,  
1Loma Linda University, Loma Linda, United States

**P 181**  
Neuroprotective role of cinnamaldehyde against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease  
*Kumar A.*,  
1Jamia Millia Islamia (A central University), Department of Biosciences, New Delhi, India

**P 182**  
Psychosocial impact of African families structure among patients with Huntington’s disease  
*Bocoum A.*,  
1Teaching Hospital of Point G, Neurology, Bamako, Mali,  
2Teaching Hospital of Kati, Internal Medicine, Bamako, Mali,  
3Teaching Hospital of Gabriel Touré, Neurology, Bamako, Mali,  
4Teaching Hospital of Point G, Psychiatry, Bamako, Mali,  
5Neurogenetics Branch, NINDS, NIH, Bethesda, United States,  
6U.S.T.T-B, FMOS, DER Public Heath, Bamako, Mali
**Topic: Ataxias, Tics, and/or Myoclonus**

**P 183**
*Taking a step back to reframe the approach – an interesting case of tardive tourettism*

*Kurz T.*, *Seigler D.*, *Char L.*

1University of California Riverside, Psychiatry, March Air Reserve Base, United States, 2University of California Riverside, Psychiatry, Riverside, United States, 3California Baptist University, Riverside, United States

**P 184**
*Incidence of oculopalatal myoclonus in post-stroke patients*

*Tadjenov M.*

1Tashkent Medical Academy, Neurology, Tashkent, Uzbekistan

**P 186**
*Clinical manifestations of SYNE1 mutation related cerebellar ataxia from Korea*

*Kim J.S.*, *Kim M.*, *Cho J.*, *Moon Y.*

1Samsung Medical Center, Sungkyunkwan University School of Medicine, Neurology, Seoul, Republic of Korea, 2Konkuk University Medical Center, Seoul, Republic of Korea

**P 187**
*The prevalence of restless legs syndrome in Edirne and its districts concomitant comorbid conditions and secondary complications*

*Güler S.*, *Caylan A.*, *Turan N.*

1Trakya University Faculty of Medicine, Department of Neurology, Edirne, Turkey, 2Trakya University Faculty of Medicine, Department of Family Medicine, Edirne, Turkey, 3Trakya University Faculty of Medicine, Department of Biostatistics, Edirne, Turkey

**P 188**
*A case of propriospinal myoclonus: Secondary form or a sleep disorder?*

*Baker N.*, *Frei K.*

1Loma Linda University, Neurology, Loma Linda, United States

**P 189**
*Effects of different training programs on postural control and beta event-related desynchronization in individuals with Parkinson's disease: A pilot study*


1Mackay Medical College, Institute of Long-term care, New Taipei City, Taiwan, 2National Yang-Ming University, Department of Physical Therapy and Assistive Technology, Taipei, Taiwan, 3Chang Gung Memorial Hospital, Department of Neurology, Linkou, Taiwan, 4Mackay Memorial Hospital, Department of Neurology, Taipei, Taiwan

**P 190**
*Delayed onset progressive spastic cerebellar ataxia and cerebellar atrophy as a delayed complication of heat stroke*

*Desai D.*, *Desai S.*

1Pramukhswami Medical College, Medicine, Anand, India, 2Pramukhswami Medical College and Shree Krishna Hospital, Neurology, Anand, India
**Topic: Gait and Other Movement Disorders**

**P 192**

**Influence of the level of cognitive impairment on gait parameters in older adults and diagnosed with Parkinson’s disease**

**Mollinedo Cardalda I.**, Pérez R.², Souto T.³, Spuch C.⁴, Cancela J.M.¹

¹University of Vigo, Research group HealthyFit, Institute of Health Research Galicia Sur (IISGS), Hospital University Complex of Pontevedra (CHOP), SERGAS, Vilagarcía de Arousa, Spain, ²University of Vigo, Research group HealthyFit, Institute of Health Research Galicia Sur (IISGS), Hospital University Complex of Pontevedra (CHOP), SERGAS, Pontevedra, Spain, ³University of Vigo, Asociación Provincial de Parkinson, Pontevedra, Spain, ⁴Institute of Health Research Galicia Sur (IISGS), Hospital University Complex of Pontevedra (CHOP), SERGAS, Pontevedra, Spain

**P 193**

**The prevalence of essential tremor in Edirne and its districts concomitant comorbid conditions**

**Güler S.¹, Caylan A.², Turan N.³**

¹Trakya University Faculty of Medicine, Department of Neurology, Edirne, Turkey, ²Trakya University Faculty of Medicine, Department of Family Medicine, Edirne, Turkey, ³Trakya University Faculty of Medicine, Department of Biostatistics, Edirne, Turkey

**P 197**

**A male patient showing abnormal gait, dysarthria and psychotic symptoms followed by genetic diagnosis**

**Choi E.J.¹, Lee D.G.², Kim J.O.¹, Kim D.H.¹, Sohn S.Y.¹, Jang S.H.¹, Kim J.G.¹, Lee S.J.¹, Yoon S.J.¹**

¹Eulji University, Department of Neurology, Daejeon, Republic of Korea, ²University of Waterloo, Department of Biomedical Sciences, Waterloo, Canada

**P 199**

**Approaching health care shaped by Generational Expectations (The AGE Study): Generational perspective related to time**

**Lin J.¹, Hengartner D.¹, Rasamesesoraj T.¹, Hogue O.¹, Li Y.¹, Wenzel O.¹, Laplante E.¹, Liang J.¹, Fernandez H.¹, Yu X.X.¹**

¹Cleveland Clinic, Movement Disorders, Cleveland, United States

**P 200**

**A study of correlation between screening tools for cognitive decline and gait status using three-dimensional gait analysis**

**Kim H.-T.¹**

¹Hanyang University, College of Medicine, Seoul, Republic of Korea

**P 201**

**A validity study of wearable accelerometer for estimating gait in Parkinson’s disease**

**Ahn J.-Y.¹**

¹Seoul Medical Center, Seoul, Republic of Korea

**P 205**

**Approaching health care shaped by Generational Expectations (The AGE Study): A perspective on technology and research**

**Rasamesesoraj T.¹, Hengartner D.¹, Lin J.¹, Hogue O.¹, Li Y.¹, Wenzel O.¹, Laplante E.¹, Liang J.¹, Fernandez H.¹, Yu X.X.¹**

¹Cleveland Clinic, Movement Disorders, Cleveland, United States

**P 206**

**Global improvement and patient satisfaction: Results from a long-term, open-label, rollover study of valbenazine in tardive dyskinesia**

**Lindenmayer J.-P.¹, Verghese C.², Marder S.³, Burke J.⁴, Jimenez R.⁴, Farahmand K.⁴, Siegert S.⁴**

¹New York University School of Medicine, New York, United States, ²Keystone Clinical Studies, LLC, Norristown, United States, ³University of California Los Angeles, David Geffen School of Medicine, Los Angeles, United States, ⁴Neurocrine Biosciences, Inc., San Diego, United States
P 207  
**Efficacy of opicapone in Parkinson’s disease patients with motor fluctuations: Results from the BIPARK I study**  
Ferreira J.¹, Lees A.², Siegert S.³, Board T.², Santos A.⁴, Pinto R.⁴, Lopes N.⁴, Nunes T.⁴, Rocha J.-F.⁴, Soares-da-Silva P.⁴.⁵  
¹Hospital de Santa Maria, Lisbon, Portugal, ²University College London, London, United Kingdom, ³Neurocrine Biosciences, Inc., San Diego, United States, ⁴BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal, ⁵University Porto, Porto, Portugal

P 208  
**Switch of double-blind opicapone, entacapone, or placebo to open-label opicapone: Efficacy results of the 1-year extension of study BIPARK I**  
Ferreira J.¹, Lees A.², Tolosa E.³, Poewe W.⁴, Banach M.⁵, Siegert S.⁶, Board T.⁶, Santos A.⁷, Lopes N.⁷, Rocha J.-F.⁷, Soares-da-Silva P.⁷.⁸  
¹Hospital de Santa Maria, Lisbon, Portugal, ²University College London, London, United Kingdom, ³Parkinson Disease Research IDIBAPS, Barcelona, Spain, ⁴Innsbruck Medical University, Innsbruck, Austria, ⁵Jagiellonian University, Cracow, Poland, ⁶Neurocrine Biosciences, Inc., San Diego, United States, ⁷BIAL-Portela & Ca SA, Sao Mamede do Coronado, Portugal, ⁸University Porto, Porto, Portugal

---

**Topic: Late Breaking Abstracts**

P 209  
**Screening of SCN11A in patients with essential tremor**  
Chan Hui Shan C.¹  
¹National Neuroscience Institute, Singapore General Hospital Pte Ltd, Singapore, Singapore

P 210  
**Generation of isogenic human G2019S Parkinson’s model**  
Dongrui M.¹, Jinyan Z.¹, Yi Z.², King T.E.¹.³.⁴  
¹Academia, Singapore, Singapore, ²Singapore General Hospital, Dept. of Clinical Research, Singapore, Singapore, ³National Neuroscience Institute of Singapore, Neurology, Singapore, Singapore, ⁴Duke NUS Graduate Medical School, Sino, Singapore

P 211  
**Is there any difference between essential and dystonic head tremor?**  
Hollý P.¹, Ulmanová O.¹, Rusz J.¹, Krupička R.³, Duspivová T.³, Růžička E.¹  
¹Charles University First Faculty of Medicine and General University Hospital, Dept. of Clinical Neuroscience, Prague, Czech Republic, ²Czech Technical University, Faculty of Electrical Engineering, Dept. of Circuit Theory, Prague, Czech Republic, ³Czech Technical University, Faculty of Biomedical Engineering, Dept. of Biomedical Informatics, Kladno, Czech Republic

P 212  
**LRP10 subcellular localization in human iPS-derived dopaminergic neurons: Implications for LRP10 dysfunction in synucleinopathies**  
Grochowska M.M.¹, Masius R.¹, Ghazvini M.², Quadri M.L.¹, Mandemakers W.¹, Bonifati V.¹  
¹Erasmus Medical Center, Department of Clinical Genetics, Rotterdam, Netherlands, ²IPS Core Facility, Erasmus Medical Center, Department of Developmental Biology, Rotterdam, Netherlands

P 213  
**PTRHD1 loss-of-function mutation in an African family with parkinsonism and intellectual disability**  
Kuipers D.¹, Carr J.², Bardien S.³, Thomas P.², Sebata B.², Breedveld G.J.¹, van Minkelen R.¹, Brouwer R.W.W.², van IJcken W.F.J.², van Slegtenhorst M.A.¹, Bonifati V.¹, Quadri M.¹  
¹Erasmus MC, Department of Clinical Genetics, Rotterdam, Netherlands, ²Stellenbosch University, Faculty of Medicine and Health Sciences, Division of Neurology, Cape Town, South Africa, ³Stellenbosch University, Faculty of Medicine and Health Sciences, Division of Molecular Biology and Human Genetics, Cape Town, South Africa, ²Erasmus MC, Center for Biomics, Rotterdam, Netherlands
CALL FOR ABSTRACTS

Submit by Nov. 23, 2018
wpc2019.org/CallAbstracts

Dr. S. Pablo Sardi
The poster and oral poster exhibition of the XXIII World Congress on Parkinson’s Disease and Related Disorders is located in the Forum Hall 3 close to the industry exhibition. Posters will be sorted by topics and numbers. The poster exhibition is open to all participants according to the opening times of the industry exhibition.

The poster size is 120cm high and 90cm wide, DIN A0 (portrait format).

Set-up times for posters / oral posters

Sunday, 19 August 2018 10:00 – 15:00

Dismantling

Tuesday, 21 August 2018 17:00 – 18:00

Posters that have not been removed within the indicated time schedule will be removed and disposed.

Oral Poster Presentation

Please note that the time allocated for your presentation is a short 4-minute oral presentation followed by 2 minutes Q&A. Given that there are additional abstracts presenting in the same session, we urge you not to exceed the time limit in order to give the other speakers time for their talks.

The Oral Poster Presentation will take place as a poster walk chaired by renowned specialists. Interested delegates can meet the authors during the time of the Oral Poster Presentation. The presentation will be directly at your poster.

Meet the poster authors during the lunch break at their posters:

**Even poster numbers:** Monday, August 20, 2018 from 12:15 – 13:15

**Uneven poster numbers:** Tuesday, August 21, 2018 from 12:15 – 13:15
Speakers Centre

The speakers centre is located on 2nd floor / Salon Lumière. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint Format 97-2007, 2010 or 2013 in ppt or pptx format, or Adobe Acrobat Reader (pdf) to guarantee slides will open successfully on an on-site PC. Prepare your presentation in 16:9 format (screens are in 16:9 format).

Speakers are asked to contact the speaker’s centre preferably one day before their presentation, or, at the latest, 90 minutes prior to the presentation.

Several PC work stations are provided in the speaker’s centre where speakers can also work on their charts. Technical staff will be glad to assist. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of presentation. Use of own technical equipment (laptop, MAC) is not allowed.

Opening Hours of the Speakers Centre

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 19 August 2018</td>
<td>11:30 – 17:30</td>
</tr>
<tr>
<td>Monday, 20 August 2018</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, 21 August 2018</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, 22 August 2018</td>
<td>07:30 – 11:00</td>
</tr>
</tbody>
</table>

The Speakers Centre and technical requirements of the congress are gratefully supported by US WorldMeds
INDEX OF AUTHORS AND SPEAKERS

A

Acharya Kumar Mrinal, Kolkata, India ......................................................... 23, 25
Albanese Alberto, Milan, Italy ................................................................. 14, 24, 26
Agid Yves, Paris, France ............................................................................. 11

B

Baumann Christian, Zurich, Switzerland ................................................... 16
Bellot Emmanuelle, Grenoble, France ....................................................... 24
Berg Daniela, Tübingen, Germany ............................................................... 13
Bergman Hagai, Jerusalem, Israel ............................................................... 11
Bhatia Kailash, London, United Kingdom .................................................. 13, 21, 26
Bhidayasiri Roongroj, Bangkok, Thailand .................................................. 13, 14
Bocoum Abdoulaye, Bamako, Mali ............................................................. 17
Bonifati Vincenzo, Rotterdam, The Netherlands ....................................... 17, 21, 29
Borgohain Rupam, Hyderabad, India ......................................................... 18, 24
Brabenec Lubos, Brno, Czech Republic ..................................................... 19
Broussolle Emmanuel, Lyon, France ........................................................... 21
Bruecke Thomas, Vienna, Austria ............................................................... 11
Buechele Fabian, Zurich, Switzerland ......................................................... 25

C

Callizot Noëlle, Gardanne, France .............................................................. 25
Calzetti Stefano, Parma, Italy ................................................................... 23
Cavallieri Francesco, Modena, Italy ........................................................... 21
Caviness John, Phoenix, United States ..................................................... 24
Cenci M. Angela, Lund, Sweden ................................................................. 11, 14
Cereda Emanuele, Pavia, Italy ................................................................... 16, 19
Chabardes Stephan, Grenoble, France ...................................................... 77
Charvin Delphine, Plan-les-Ouates, Switzerland ....................................... 26
Chung Sun Ju, Seoul, Republic of Korea .................................................. 19
Coelho Miguel, Lisbon, Portugal ............................................................... 16

D

Dayal Vish, London, United Kingdom ......................................................... 77
Debu Bettina, Grenoble, France ................................................................. 16
Derkinderen Pascal, Nantes, France ........................................................... 13
Desai Soaham, Anand, India .................................................................... 26
Dham Bhavpreet, Rochester, United States ............................................... 14
Dickson Dennis, Jacksonville, United States ............................................. 29
Di Rocco Alessandro, New York, United States ......................................... 29
Dressler Dirk, Hannover, Germany ............................................................. 17, 21
Durif Franck, Clermont Ferrand, France .................................................... 15
Espay Alberto, Cincinnati, United States .......................... 22, 77

Fernandez Hubert, Cleveland, United States .......................... 11, 21, 28, 29, 77
Flamand-Roze Emmanuel, Paris, France ............................ 18, 26
Frei Karen, Loma Linda, United States ................................. 21, 26, 77
Friedman Jennifer, San Diego, United States .......................... 23
Fujioka Shinsuke, Fukuoka, Japan ........................................ 14

Gamaleya Anna, Moscow, Russian Federation ............................ 14
Gao Chao, Shanghai, China .................................................. 19
Giannini Giulia, Bologna, Italy ................................................. 15
Goldman Jennifer, Chicago, United States ............................... 11, 22
Gonzalez Victoria, Montpellier, France ...................................... 15
Grabli David, Paris, France ................................................... 18
Gu Lihua, Nanjing, China ..................................................... 14
Guttmann Mark, Toronto, Canada ............................................ 18

He Lu, Shanghai, China ...................................................... 19, 25
Hedera Peter, Nashville, United States ...................................... 24
Hengartner Diana, Cleveland, United States .............................. 17
Henriques Alexandre, Gardanne, France .................................. 18
Hipp Géraldine, Belvaux, Luxembourg .................................... 14
Hirnyi Yaroslau Compta, Barcelona, Spain ................................. 18
Hirsch Etienne, Paris, France ................................................ 29

Iakovleva Olga, Moscow, Russian Federation ............................. 18
Ibrahim Wael, Cairo, Egypt ................................................... 26
Isaacson Stuart, Boca Raton, United States ............................... 77
Isaias Ioannis, Wuerzburg, Germany ....................................... 13, 15, 16

Jimenez-Shahed Joohi, Houston, United States .......................... 17, 21
Jog Mandar, London, Canada ............................................... 26

Kalia Lorraine, Toronto, Canada ............................................ 13
Kandadai Rukmini Mridula, Mumbai, India ................................ 24, 26
<table>
<thead>
<tr>
<th>Name</th>
<th>Location</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karl Jessica</td>
<td>Chicago, United States</td>
<td>15</td>
</tr>
<tr>
<td>Khatri Dharmendra</td>
<td>Mumbai, India</td>
<td>18</td>
</tr>
<tr>
<td>Kholmuratova Bakhtigul</td>
<td>Tashkent, Uzbekistan</td>
<td>17</td>
</tr>
<tr>
<td>Kim Mi Sun</td>
<td>Seoul, Republic of Korea</td>
<td>15</td>
</tr>
<tr>
<td>Kim Minkyeeong</td>
<td>Seoul, Republic of Korea</td>
<td>17</td>
</tr>
<tr>
<td>Kim Yun Joong</td>
<td>Anyang, Republic of Korea</td>
<td>22</td>
</tr>
<tr>
<td>Klobusiakova Patricia</td>
<td>Brno, Czech Republic</td>
<td>22</td>
</tr>
<tr>
<td>Krauss Joachim</td>
<td>Hannover, Germany</td>
<td>28</td>
</tr>
<tr>
<td>Kulisevsky Jaime</td>
<td>Barcelona, Spain</td>
<td>13</td>
</tr>
<tr>
<td>Kumar Hrishikesh</td>
<td>West Bengal, India</td>
<td>16</td>
</tr>
<tr>
<td>Lal Vivek</td>
<td>Chandigarh, India</td>
<td>22</td>
</tr>
<tr>
<td>Laurencin Chloé</td>
<td>Lyon, France</td>
<td>26</td>
</tr>
<tr>
<td>Lee Chong Sik</td>
<td>Seoul, Republic of Korea</td>
<td>15</td>
</tr>
<tr>
<td>Lehericy Stephane</td>
<td>Paris, France</td>
<td>13</td>
</tr>
<tr>
<td>Lew Mark</td>
<td>Los Angeles, United States</td>
<td>16, 19</td>
</tr>
<tr>
<td>Liang Yanran</td>
<td>Guangzhou, China</td>
<td>19</td>
</tr>
<tr>
<td>Lim Thien T, George Town</td>
<td>Malaysia</td>
<td>24, 26</td>
</tr>
<tr>
<td>Lin Danyu</td>
<td>Guangzhou, China</td>
<td>19</td>
</tr>
<tr>
<td>Litvan Irene</td>
<td>San Diego, United States</td>
<td>15</td>
</tr>
<tr>
<td>Liu Hsin-Hsuan</td>
<td>Taipei, Taiwan</td>
<td>19</td>
</tr>
<tr>
<td>Maeda Tetsuya</td>
<td>Morioka, Japan</td>
<td>26</td>
</tr>
<tr>
<td>Mandal Moulika</td>
<td>Mumbai, India</td>
<td>14</td>
</tr>
<tr>
<td>Mari Zoltan, Cleveland</td>
<td>United States</td>
<td>22, 26</td>
</tr>
<tr>
<td>Martino Davide</td>
<td>Calgary, Canada</td>
<td>21</td>
</tr>
<tr>
<td>Mehanna Raja</td>
<td>Houston, United States</td>
<td>14, 17</td>
</tr>
<tr>
<td>Merello Marcelo</td>
<td>Buenos Aires, Argentina</td>
<td>15, 18</td>
</tr>
<tr>
<td>Mestre Tiago</td>
<td>Ottawa, Canada</td>
<td>21</td>
</tr>
<tr>
<td>Millot Mathilde</td>
<td>Lyon, France</td>
<td>25</td>
</tr>
<tr>
<td>Moro Elena</td>
<td>Grenoble, France</td>
<td>11, 13, 17, 24, 28, 77</td>
</tr>
<tr>
<td>Mueller Thomas</td>
<td>Berlin, Germany</td>
<td>18, 77</td>
</tr>
<tr>
<td>Naz Falaq</td>
<td>Aligarh, India</td>
<td>19</td>
</tr>
<tr>
<td>Nazmuddin Muhammad</td>
<td>Groningen, The Netherlands</td>
<td>14</td>
</tr>
<tr>
<td>Obese Vida</td>
<td>Kumasi, Ghana</td>
<td>19</td>
</tr>
<tr>
<td>Okun Michael</td>
<td>Gainesville, United States</td>
<td>11</td>
</tr>
<tr>
<td>Ondo William</td>
<td>Houston, United States</td>
<td>24</td>
</tr>
<tr>
<td>Ou Ruwei</td>
<td>Chengdu, China</td>
<td>22</td>
</tr>
</tbody>
</table>
P

Pablo-Fernández Eduardo De, London, United Kingdom .......................................................... 25
Pagan Fernando, Washington DC, United States ................................................................. 18, 25
Pahwa Rajesh, Kansas City, United States ............................................................................ 25
Pal Pramod, Bengaluru, Karnataka, India ............................................................................... 16, 18
Patel Shnehal, Cleveland, United States ............................................................................... 26
Pfeiffer Ronald, Portland, United States ............................................................................... 11, 16
Pilotto Andrea, Brescia, Italy ............................................................................................... 14, 23
Postuma Ronald, Montreal, Canada .................................................................................... 13
Pozzi Nicolò G., Wuerzburg, Germany ................................................................................. 17
Prange Stéphane, Bron, France ........................................................................................... 25
Prasad Shweta, Bangalore, India ........................................................................................... 26
Puschmann Andreas, Lund, Sweden ...................................................................................... 29

R

Radder Danique, Nijmegen, The Netherlands .................................................................... 25
Reichmann Heinz, Dresden, Germany .................................................................................... 16
Rektorova Irena, Brno, Czech Republic .................................................................................. 15, 22
Riederer Peter, Wuerzburg, Germany .................................................................................... 11, 13, 29
Rosales Raymond, Quezon City, Philippines ....................................................................... 13, 21

S

Sandroni Paola, New York, United States ............................................................................... 16
Schwarzschild Michael, Boston, United States ..................................................................... 11, 23
Sette Anna Luce, Grenoble, France ....................................................................................... 15
Shah Binit, Charlottesville, United States ........................................................................... 24
Shang Hui-Fang, Chengdu, China ........................................................................................ 11, 24
Shimo Yasushi, Tokyo, Japan ............................................................................................... 25
Shin Cheol Min, Seongnam, Republic of Korea .................................................................... 25
Siegert Scott, San Diego, United States ................................................................................ 17
Simuni Tanya, Chicago, United States .................................................................................. 15, 21, 28, 77
Singh Himanshu Narayan, Delhi, India ............................................................................... 22
Smolders Stefanie, Antwerp, Belgium .................................................................................. 22
Sringean Jirada, Bangkok, Thailand ...................................................................................... 26
Stamelou Maria, Athens, Greece ........................................................................................... 16, 23, 26
Stoessl Jon, Vancouver, Canada .......................................................................................... 28

T

Tagliati Michele, Los Angeles, United States ....................................................................... 24
Tamuli Dibashree, New Delhi, India ...................................................................................... 17
Tan Eng-King, Singapore, Singapore .................................................................................... 22, 24, 29
Tan Shi-Ni, Singapore, Singapore ........................................................................................ 17
Tanner Caroline, San Francisco, United States .................................................................... 13, 16
Teng Chen Celeste Yan, Singapore, Singapore ..................................................................... 23
INDEX OF AUTHORS AND SPEAKERS

Thobois Stephane, Lyon, France ......................................................... 13, 28, 77
Torres-Russotto Diego, Omaha, United States ........................................ 16, 23
Truong Daniel, Fountain Valley, United States ........................................ 13, 21

U
Uc Ergun, Iowa City, United States .......................................................... 11

V
Verhagen Leonard, Chicago, United States .............................................. 14, 18
Vidailhet Marie, Paris, France ................................................................. 11, 21, 26, 29
Volkmann Jens, Wuerzburg, Germany ...................................................... 17, 77
Vuletic Vladimira, Rijeka, Croatia ............................................................. 15

W
Walsh Ryan, Phoenix, United States ......................................................... 22
Weintraub Daniel, Philadelphia, United States .......................................... 14, 26
Welter Marie Laure, Paris, France .............................................................. 24
Willemijn van Beek Judith Jantine, Lucerne, Switzerland ......................... 19
Wolters Erik Ch., Amsterdam, The Netherlands ....................................... 11, 29
Wu Yih-Ru, Taoyuan, Taiwan ................................................................. 24
Wu Yuncheng, Shanghai, China .............................................................. 25

Y
Yang YoungSoon, Seoul, Republic of Korea ........................................... 19
Yoon Won Tae, Seoul, Republic of Korea .................................................. 17, 23
Yunusov Farkhod, Tashkent, Uzbekistan .................................................. 23

Z
Zesiewicz Theresa, Tampa, United States ............................................... 18, 23
Join us for an immersive and interactive exhibit that illustrates life with Parkinson’s disease and the types of OFF episodes that patients experience.

LEARN MORE about the struggles of Maggie*, a patient with moderate-to-advanced Parkinson’s disease, and the Little Big Things™ that may improve her daily life.

*Fictional patient for illustration only.
GENERAL CONGRESS
INFORMATION
REGISTRATION

Congress Registration Counter
All congress materials and documentations will be available at the congress registration counter located at Foyer Lumière at the Centre de Congès de Lyon.

Opening hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, 19 August 2018</td>
<td>10:00 – 19:00</td>
</tr>
<tr>
<td>Monday, 20 August 2018</td>
<td>07:00 – 19:00</td>
</tr>
<tr>
<td>Tuesday, 21 August 2018</td>
<td>07:00 – 20:00</td>
</tr>
<tr>
<td>Wednesday, 22 August 2018</td>
<td>07:30 – 13:00</td>
</tr>
</tbody>
</table>

During these opening hours the congress registration counter can be reached at: +33 472-822 600

Registration Fees

<table>
<thead>
<tr>
<th>Registration Types</th>
<th>On-site Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Congress Ticket*</td>
<td>€ 750,00</td>
</tr>
<tr>
<td>Reduced Fee**</td>
<td>€ 450,00</td>
</tr>
<tr>
<td>Student Ticket***</td>
<td>€ 350,00</td>
</tr>
</tbody>
</table>

*Special conditions for Travel Grant applicants according to website.
** Participants from lower & lower middle income countries: List according to WHO criteria on website.
*** Students: Copy of student ID required | Residents/Fellows/Trainees: Born after 1 January 1987 and/or still in training. Copy of official document indicating age or a letter stating training status by employer required.

The registration fee for delegates includes:

- Access to the Scientific Sessions
- Access to the Exhibition
- Free copy of the education book Parkinson Disease and Other Movement Disorders (subject to availability)
- Certificate of Attendance
- Welcome Reception on Sunday, 19 August 2018

On-site Registration
On-site registration will be processed on a first come, first served basis. Priority will be given to pre-registered delegates.

Selfprint
Please use the barcode, which should be sent to you via e-mail, to print out your name badge at the provided printing stations.
Name Badge
All participants are requested to wear their name badges at all times during the congress.

Executive Board = Purple   Exhibitor = Green   Delegate = White
Faculty = Blue   Staff = Red

Certification
The European Accreditation Committee in CNS (EACIC) has granted 24.5 CME credits to this event. To obtain your CME credits, please fill in the online event evaluation form at www.eacic.eu.
Deadline: 22 October 2018

Please follow the below steps to receive your CME credits:
• Go to the EACIC website www.eacic.eu
• Click on the CME logo (in the blue bar on the right hand side of the webpage)
• Choose the option “I am already registered” or “I am not registered”
• Log on or register
• Choose point 1 or 2
• Choose the event for which you would like to receive credits
• Complete the evaluation form
• Press “save”

Your CME certificate will be automatically emailed to the address provided

Certificate of Attendance
Please contact the registration counter to obtain a certificate of attendance.

TRAVEL GRANTS

This year’s Congress Travel Awards are gratefully supported by the International Association of Parkinsonism and Related Disorders, the Parkinson’s and Movement Disorder Foundation and individual supporters.

The awards are aimed at promoting participation in the Congress by young researchers worldwide. Applicants must be under the age of 35 at the opening date of the Congress, 19 August 2018. The deadline for Travel Grant applications was 23 April 2018.

Further information is available on the Congress website.
Lyon Convention Centre
50, quai Charles de Gaulle
69463 Lyon, France

How to get there:
The Convention Centre is within walking distance to major hotels, 10 minutes to the Lyon Part Dieu high-speed train station and 30 minutes from the Lyon Saint-Exupéry International Airport.

Arriving by plane: Lyon Saint Exupéry airport is one of the biggest airports in France and is located 30 minutes away from the city center. All major airlines serve Lyon from more than 100 destinations and hubs worldwide. The Rhône express tram runs up to every 15 minutes between airport and city center, travel duration 30 minutes.

Arriving by Train: Lyon is part of the French TGV high-speed network. Long distance trains arrive at Lyon Part Dieu station.

Arriving by car: The Lyon Convention Centre is situated close to the Lyon Périphérique Nord (Northern Ring Road). Parking space is available next to the Convention Centre. Parking fees are not included in the registration fee.

Public Transportation: The Lyon Convention Centre is connected by 3 bus and trolley lines to the Lyon Public transportation system.
Abstract E-Book
The abstract book contains all accepted abstracts that have been submitted by authors from around the globe on topics related to Parkinson disease and other movement disorders. All abstracts have been reviewed by a panel of reviewers and the book is now provided as a download.

Charging station mobile devices
You are welcome to recharge your mobile devices at the Sunovion Pharmaceuticals, Inc. charging lounge in the exhibition area.

Climate
Expect a moderate climate in August with sunny days and temperature up to 28°C.

Cloakroom
A cloakroom is available next to the registration counter. You can also store your luggage there.

Coffee breaks
Coffee and tea are provided during the breaks in the exhibition area and are gratefully supported by Sunovion Pharmaceuticals, Inc.

Currency
The official French currency is the Euro. Exchange of foreign currency is available at the airport, train station, at most hotels, banks and exchange offices.

Disclaimer
The Organizers cannot accept liability for injuries or losses of whatever nature incurred by participants, nor for loss of or damage to their luggage and/or personal belongings.

Language
The official language of the International Association Parkinsonism and Related Disorders is English. However, all participants are encouraged to join discussions regardless of their fluency in English, as the exchange of ideas and critical evaluation of presentation is the main purpose of the entire Congress.

Mobile phones
Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions.

Personal Insurance
We recommend that all participants take out personal travel and health insurance for their trip.
Press
Journalists should bring their press ID and register at the congress registration counter.

Program Changes
The Organizers cannot assume liability for any changes in the program due to external unforeseen circumstances.

Recording
Cameras, video cameras or audio recording devices are not permitted in the session rooms. Any recording/documentation of sessions is strictly forbidden.

Safety
As in all major cities and congress venues, people should take care of their personal belongings. It is not advised to wear your congress badge outside the XXIII IAPRD Congress activities. Please have your handbag, bag, backpack etc. ready for inspection by security officers while entering the congress venue.

Smoking Policy
Smoking is not allowed at the venue; the meeting is a non-smoking event.

Visa
France is part of the European Schengen area. The entry formalities for France vary accordingly to the country of origin. A letter of invitation can be issued by the congress and registration office.

WLAN/Wi-Fi
Complimentary Wi-Fi access is available in the Lyon Convention Centre and is gratefully supported by Sunovion Pharmaceuticals, Inc.
About the International Association of Parkinsonism and Related Disorders

More than fifty years ago, the International Association of Parkinsonism and Related Disorders was established by the World Federation of Neurology to promote and monitor research developments, as well as to foster communication among neuroscientists in the field. Today, IAPRD is an international, professional association of clinicians, scientists and other healthcare professionals who are interested in neurodegenerative disorders like Parkinson's disease, secondary parkinsonisms, hyperkinetic and hypokinetic movement disorders, and more generally any disorder affecting muscle tone and motor control. The most common clinical disorders and/or symptoms of interest to us are:

- Genetic and idiopathic Parkinson's disease and other parkinsonism
- Genetic and idiopathic disorders with dystonia
- Huntington's disease and other disorders with chorea
- Cerebellar disorders
- Tremor, myoclonus, tics, ballism
- Huntington’s disease, chorea and Gilles de la Tourette’s syndrome
- Psychogenic and psychiatric movement disorders
- Movement disorders-related non-motor disorders, such as disorders of the autonomic nervous system, mood disorders, sleep disorders (including: excess daytime sleepiness, REM sleep behaviour disorders, restless legs syndrome, and periodic limb movements), and psychiatric disorders (including: impulse control disorders, executive dysfunction, dementia, delusions and hallucinations)

The IAPRD has associate members, full members, and honorary members.

Reasons to become a member:
- Free subscription to our journal
- Access to hot scientific items
- Discounts to our publications

Further information is available at www.iaprd.org
Simply Advanced

STIMVIEW™ Technology makes directional programming intuitive and simple.”
IAPRD COMMITTEES

Scientific Program Executive Committee
Hubert Fernandez, Chair (USA)  
Alberto Albanese (Italy)  
Roongroj Bhidayasiri (Thailand)  
Mark Lew (USA)  
Elena Moro (France)  
Andreas Puschmann (Sweden)  
Peter Riederer (Germany)  
Tanya Simuni (USA)  
Stephane Thobois (France)  
Daniel Truong (USA)  
Marie Vidailhet (France)  
Erik Ch. Wolters (The Netherlands)  
Zbigniew Wszolek (USA)

Scientific Program Committee
Tanya Simuni, Chair (USA)  
Christian Baumann (Switzerland)  
Mohit Bhatt (India)  
Emanuele Cereda (Italy)  
Shengdi Chen (China)  
Bettina Debu (France)  
Alessandro Di Rocco (USA)  
Karen Frei (USA)  
Shinsuke Fujioka (Japan)  
Etienne Hirsch (France)  
Jahirul Hoque (Bangladesh)  
Ioannis Isaias (Germany)  
Saltanat Kamenova (Kazakhstan)  
Joachim Krauss (Germany)  
Hrishikesh Kumar (India)  
Thomas Müller (Germany)  
Fernando Pagan (USA)  
Rajesh Pahwa (USA)  
Pramod Pal (India)  
Gulnora Rakhimbaeva (Ukraine)  
Paola Sandroni (USA)  
Jooji Jimenez-Shahed (USA)  
Hui-Fang Shang (China)  
Fabrizio Stocchi (Italy)  
Jon Stoessl (Canada)  
Michele Tagliati (USA)  
Marie Laure Welter (France)  
Yun-Cheng Wu (China)

Abstract Review Committee
Christian Baumann, Chair (Switzerland)  
Yih-ru Wu, Co-Chair (Taiwan)  
Jooji Jimenez-Shahed (USA)  
Petr Kanovsky (Czech Republic)  
Dirk Dressler (Germany)  
David Grabli (France)  
Eng-King Tan (Singapore)  
Irena Rektorova (Czech Republic)

Award Committee
Peter Riederer, Chair (Germany)  
Peter Hedera (USA)  
Elena Moro (France)  
Pramod Pal (India)  
Nicolas Phielipp (USA)  
Paola Sandroni (USA)  
Daniel Truong (USA)
Video Review Committee
Marie Vidailhet, Chair (France)
Alberto Albanese, Co-Host (Italy)
Kailash Bhatia, Co-Host (United Kingdom)
Roongroj Bhidayasiri (Thailand)

Emanuel Flamand-Roze (France)
Thien Thien Lim (Malaysia)
Rukmini Mridula Kandadai (India)
Maria Stamelou (Greece)

Local Organizing Committee
Stephane Thobois, Chair (France)
Marie Vidailhet, Co-Chair (France)
Jean-Philippe Azulay (France)
Philippe Damier (France)

Franck Durif (France)
Jean-Luc Houeto (France)
Wassilios Meissner (France)
Christine Tranchant (France)

Industry Liaison Committee
Mark F. Lew, Chair (USA)
Alberto Albanese (Italy)
Stuart Isaacson (USA)
Joachim Krauss (Germany)

Rajesh Pahwa (USA)
Michele Tagliati (USA)
Diego Torres Russotto (USA)

World Congress Ambassador Committee
Zizyo Ak (Uzbekistan)
Jasem Al-Hashel (Kuwait)
Alberto Albanese (Italy)
Oscar Bernal (Colombia)
Tauhidul Islam Chowdhury (Bangladesh)
Roland Dominic G. Jamora (Philippines)
Beom Jeon (Republic of Korea)
Jahirul Hoque (Bangladesh)

Harsha Gunasekara (Sri Lanka)
Hrishikesh Kumar (India)
Thien Thien Lim (Malaysia)
Vladimir Miletić (Croatia)
Thomas Müller (Germany)
Eng-King Tan (Singapore)
Tai Tran (Vietnam)
Vladimira Vuletić (Croatia)
This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. This section contains information that is promotional in nature, distinct from the scientific/educational elements of the main CME/CPD event.
Code of Transparency
Interplan publishes the conditions and the scope of the support provided by EFPIA member companies to the IAPRD Congress on a voluntary basis. The publication will be carried out before and during the execution of the Congress.
For the industry partners mentioned, we are herewith providing information about their overall support within the framework of the IAPRD Congress 2018.
EXHIBITORS

Company
ABBOTT
AbbVie, Inc.
BOSTON SCIENTIFIC
CNS – CAMPUS NEUROLÓGICO
EVER Pharma France SAS
Sunovion Pharmaceuticals

Booth No.
C 02
C 04
C 05
D 01
C 03
B 01

Exhibition opening times
Sunday, 19 August 2018  14:00 - 20:30
Monday, 20 August 2018  09:00 - 18:00
Tuesday, 21 August 2018  09:00 - 17:30
We kindly thank all our sponsors for their support!
Sponsor names are in alphabetical order.

We are pleased to inform you that the IAPRD Congress 2018 is COMPLIANT in accordance with the principles and standards set out in the MedTech Europe Code of Ethical Business Practice.
This decision is posted on www.ethicalmedtech.eu

This event is supported, in part, by funding from industry. All support will be managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support.
Monday, 20 August 2018

Corporate Session

Debating OFF Phenomenon in Parkinson Disease: Lessons Learned after 40 Years
Chair: Hubert Fernandez, Cleveland, United States
12:15 – 12:35

Why debating OFF phenomenon remains relevant today as it was 40 years ago
Speaker: Hubert Fernandez, Cleveland, United States
12:35 – 12:55

Position 1: We have made great strides in addressing OFF phenomenon in PD; it is time to move on
Speaker: Tanya Simuni, Chicago, United States
12:55 – 13:15

Position 2: We have a long way to go in understanding and treating OFF phenomenon in PD
Speaker: Alberto Espay, Cincinnati, United States
13:15 – 13:45

Panel Discussion
Supported by an unrestricted grant from Sunovion Pharmaceuticals

Corporate Session

New Trends and Horizons in Deep Brain Stimulation (DBS)
Chair: Elena Moro, Grenoble, France
Chair: Stephane Thobois, Lyon, France
12:15 – 12:35

Is there potential to expand the capabilities of DBS with directionality?
Surgical perspective
Speaker: Stephan Chabardes, Grenoble, France
12:35 – 12:55

Short pulse width: Pathway selectivity and therapeutic window outcomes
Speaker: Vish Dayal, London, United Kingdom
12:55 – 13:15

Directionality – Programming guidelines & workflow perspective:
Role of visualization
Speaker: Jens Volkmann, Wuerzburg, Germany
Supported by an unrestricted grant from Boston Scientific

Tuesday, 21 August 2018

Corporate Session

Answering the Most Relevant Questions on Motor Fluctuations in Parkinsons Disease
12:15 – 13:45

Why do we keep developing drugs for motor fluctuations in Parkinsons disease?
Speaker: Karen Frei, Loma Linda, USA
12:15 – 12:35

Are the newest treatment options available for motor fluctuations worth their hype?
Speaker: Thomas Mueller, Berlin, Germany
12:35 – 12:55

Are the next generations of drugs under development for motor fluctuations more promising than our current armamentarium?
Speaker: Stuart Isaacson, Boca Raton, United States
12:55 – 13:15

Panel Discussion
Supported by an unrestricted grant from Neurocrine Biosciences and Bial
Organizer of the scientific conference

IAPRD
The International Association of Parkinsonism and Related Disorders
Van Eeghenstraat 83, 1071 EX Amsterdam, The Netherlands
E-Mail: info@iaprd.org
Website: www.iaprd.org

Congress and Exhibition Office

INTERPLAN
Congress, Meeting & Event Management AG
Office Hamburg
Kaiser-Wilhelm-Strasse 93, 20355 Hamburg, Germany
Phone: +49 40 325092-37 / Fax: +49 40 325092-44
E-mail: IAPRD@interplan.de
Website: www.interplan.de

DATA PROTECTION

INTERPLAN AG handles all personal data according to the laws of § 4 under the Federal Data Protection Act. For your registration to a congress organized by Interplan, the collecting, saving and processing of your personal data is imperative. This is done solely as a means of the organization and completion of the event. The collected data will only be passed onto third parties that are directly involved with the running of the congress and when the organizational procedure makes this necessary (operator, hotel, visa, social program etc.).

For further information regarding the Data Protection see our website www.iarpd-world-congress.com.

If you do not want to receive information on future congresses related to the subject of this event: Declaration of consent can be retracted at any time by sending a message to Interplan AG, Landsberger Strasse 155, 80687 München, iaprd@interplan.de
Debating OFF Phenomenon in Parkinson’s Disease: Lessons Learned after 40 Years

Monday, 20 August 2018
12:15 – 13:45
Lunch to be provided - optional

Lyon Convention Centre
Forum 1

Program:
• Why debating OFF phenomenon remains relevant today as it was 40 years ago.
  (Hubert Fernandez, MD)
• Position 1: We have made great strides in addressing OFF phenomenon in PD; it is time to move on.
  (Tatyana Simuni, MD)
• Position 2: We have a long way to go in understanding and treating OFF phenomenon in PD.
  (Alberto Espay, MD)
• Panel Discussion

This is a non-CME program sponsored by Sunovion Pharmaceuticals Inc. and the speakers are consultants of Sunovion.